Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение лёгочной гипертензии

СПИСОК ЛИТЕРАТУРЫ

  1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:1801913. https://doi. org/10.1183/13993003.01913-2018
  2. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022; 43(38):3618– 3731. http://dx.doi.org/10.1093/eurheartj/ehac237
  3. Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомен-
  4. дации по диагностике и лечению лёгочной гипертензии. Терапев- тический архив 2014;9:4–23.
  5. [Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskii Arkhiv. 2014;86(9):4-23 (In Russ.)]
  6. Мартынюк Т.В. Лёгочная гипертензия: диагностика и лечение. Москва, 2018. Серия Библиотека ФГБУ «НМИЦ кардиологии»
  7. Минздрава России. ISBN 978-5-6040008-0-9
  8. [Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018. Series Library “National Medical Research Center of Cardiology” of the Ministry of Health of Russia (In Russ.). ISBN 978- 5-6040008-0-9]
  9. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015;46(4):903-975. http:// dx.doi.org/10.1183/13993003.01177-2015
  10. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., др. Клинические ре- комендации по диагностике и лечению хронической тромбоэмбо- лической лёгочной гипертензии. (I часть). Терапевтический архив 2016; 88(9):90-101. https://doi.org/10.17116/terarkh201688990-101 [Chazova I.E., Martynyuk T.V., Filippov E.V., et al. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. (Part I). Therapeutic Archive 2016;88(9):90-101 (in Russ.). https://doi.org/10.17116/terarkh201688990-101]
  11. Kim N.H., Delcroix M., Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53:1801915. https://doi. org/10.1183/13993003.01915-2018
  12. Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:69-78. https://doi.org/10.1016/j.ijcard.2018.08.079
  13. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские кли- нические рекомендации по диагностике и лечению лёгочной ги- пертензии (2019). Евразийский Кардиологический Журнал 2020;
  14. 1:78-122. https://doi.org/10.38109/2225-1685-2020-1-78-122
  15. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension (2019). Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi. org/10.38109/2225-1685-2020-1-78-122]
  16. Чазова И.Е., Мартынюк Т.В. Лёгочная гипертензия. – Москва. Практика. 2015; 928с.
  17. [Chazova I.E., Martynyuk T.V. Pulmonary hypertension. – Moscow. Practice. 2015; 928 pp. (In Russ.)]
  18. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111. https://doi.org/10.1161/ circulationaha.104.488486
  19. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Лёгочная артериаль- ная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив 2019; 91(1):10–31. https://doi.org/10.26442/00403660.2019.01.000024
  20. [Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh. 2019 Mar 10;91(1):24-31. (in Russ.). https://doi.org/ 10.26442/00403660.2019.01.000024]
  21. Chazova IE, Martynyuk TV, Valieva ZS, et al. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. BioMed Research International. 2020:6836973. PMID: 32626754. https://doi.org/10.1155/2020/6836973
  22. Чазова И.Е., Горбачевский С.В., Мартынюк Т.В., др. Евразийские рекомендации по диагностике и лечению лёгочной гипертензии, ассоциированной с врождёнными пороками сердца у взрослых (2021). Евразийский кардиологический журнал. 2022;2:6-70. https://doi.org/10.38109/2225-1685-2022-2-6-7
  23. [Chazova I.E., Gorbachevskij S.V., Martynyuk T.V., et al. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian heart journal. 2022;(2):6-70. (In Russ.). https://doi.org/10.38109/2225- 1685-2022-2-6-70]
  24. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV- related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113. https://
  25.  
  26. doi.org/10.1164/rccm.200704-541oc
  27. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno- occlusive disease. Eur Respir J 2009;33:189–200. https://doi. org/10.1183/09031936.00090608
  28. Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-
  29. 54. https://doi.org/10.1093/eurheartj/ehv512
  30. Мартынюк Т.В. «Лёгочная гипертензия вследствие патологии ле- вых отделов сердца». Глава в руководстве для врачей «Лёгочная гипертензия» под ред. Авдеева С.Н. (2 издание). ГЭОТАР-МЕДИА, Москва, 2019. С. 213-254.
  31. [Martynyuk T.V. «Pulmonary hypertension due to pathology of the left heart». Chapter in the manual for doctors «Pulmonary hypertension», ed. Avdeeva S.N. (2nd edition). GEOTAR-MEDIA, Moscow, 2019. pp. 213-254 (in Russ.)]
  32. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194. https://doi.org/10.1164/rccm.200401-006oc
  33. Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol 2013; 168(3):e89–e90. https://doi.org/10.1016/j. ijcard.2013.07.129
  34. Leon-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6:147-157. https://doi.org/10.1089/ham.2005.6.147
  35. Авдеев С.Н., Барбараш О.Л., Баутин А.Е., др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипер- тензия. Клинические рекомендации 2020. Российский кардиоло- гический журнал. 2021;26(12):4683. https://doi.org/10.15829/1560- 4071-2021-4683
  36. [Avdeev S.N., Barbarash O.L., Bautin A.E., et al. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.) https://doi. org/10.15829/1560-4071-2021-4683]
  37. Montani D, Girerd B, Jais X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2020; 58: 2004229. https://doi.org/10.1183/13993003.04229-2020
  38. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34(4):888–894. https://doi.org/10.1183/09031936.00145608
  39. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297–3317. https://doi.org/10.1093/eurheartj/ehz641
  40. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8:873–884. https://doi.org/10.1016/s2213-2600(20)30317-9
  41. Frost A, Badesch D, Simon JR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53:1801904. https://doi. org/10.1183/13993003.01904-2018
  42. Morrell N, Adnot S, Archer S, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S20-S31. https://doi.org/10.1016/j.jacc.2009.04.018
  43. Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:4–10. https://doi.org/10.1016/j.ijcard.2018.09.070
  44. Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:53–62. https://doi.org/10.1016/j.ijcard.2018.08.080
  45. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41:1292– 1301. https://doi.org/10.1183/09031936.00079512
  46. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:1801914. https://doi.org/10.1183/13993003.01914-2018
  47. Наконечников С.Н., Зыков К.А., Мартынюк Т.В., др. Профиль про- воспалительных маркеров у пациентов с различными формами лёгочной гипертензии. Системные гипертензии 2010; 3:61-67. https://doi.org/10.26442/SG28888
  48. [Nakonechnikov SN, Zykov KA, Martynyuk TV, et al. Profil'provospalitel'nykh markerov u patsientov s razlichnymi formami legochnoy gipertenzii. Systemic Hypertension 2010;7(3):61-66. (in Russ.) https://doi.org/10.26442/SG28888]Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26(143):160112. https://doi.org/10.1183/16000617.0112-2016
  49. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Лёгочная артери- альная гипертензия, ассоциированная с врождёнными пороками сердца у взрослых. Методическое пособие./ НЦССХ им. А. Н. Ба- кулева РАМН, 2016 г. ISBN: 978-5-7982-0368-0
  50. [Bockeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart defects in adults. Methodological manual./ Bakulev Center for Cardiovascular Surgery, 2016. (in Russ.). ISBN: 978-5-7982-0368-0]
  51. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306–322. https://doi. org/10.1016/s2213-2600(15)00543-3
  52. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ 2021; 11:2045894020977300. https://doi. org/10.1177/2045894020977300
  53. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107(2):216–223. https://doi.org/10.7326/0003-4819-107-2-216
  54. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (2):156–163. https://doi.org/10.1161/circulationaha.109.911818
  55. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137(2):376–387. https://doi.org/10.1378/chest.09-1140
  56. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168(2):871–880. https://doi. org/10.1016/j.ijcard.2012.10.026
  57. Чазова И.Е., Архипова О.А., Валиева З.С., др. Лёгочная гипертен- зия в России: первые результаты национального регистра. Тера- певтический архив 2014; 86(9):56-64.
  58. [Chazova IE, Arkhipova OA, Valieva ZS, et al. Pulmonary hypertension in Russia: The first results of the national register. Terapevticheskii Arkhiv. 2014;86(9):56-64. (In Russ.)]
  59. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019; 53(6):1900985. https://doi.org/10.1183/13993003.00985-2019
  60. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472. https:// doi.org/10.1056/nejmra010902
  61. Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57(6):2002828. https://doi.org/10.1183/13993003.02828-2020
  62. Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018 Jul;107(7):548-553. https://doi.org/10.1007/ s00392-018-1215-5
  63. Чазова И.Е., Валиева З.С., Наконечников С.Н. др. Особенности клинико-функционального и гемодинамического профиля, ле- карственной терапии и оценка прогноза у пациентов с неопера- бельной хронической тромбоэмболической и идиопатической лёгочной гипертензией по данным Российского регистра. Тера- певтический архив 2019; 91(9):77-87. https://doi.org/10.26442/004
  64. 03660.2019.09.000343
  65. [Chazova IE, Valieva ZS, Nakonechnikov SN, et al. Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry. Terapevticheskii arkhiv 2019;91(9):77-87. (in Russ.) https://doi.org/10.26442/0040366 0.2019.09.000343]
  66. Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465. https://doi.org/10.1183/13993003.00465-
  67. 2017
  68. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские рекомендации по диагностике и лечению хронической тром- боэмболической легочной гипертензии (2020). Евразийский Кардиологический Журнал. 2021;(1):6-43. https://doi. org/10.38109/2225-1685-2021-1-6-43
  69. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian heart journal. 2021;(1):6-43. (In Russ.) https://doi.org/10.38109/2225- 1685-2021-1-6-43]
  70. Алокова Ф.Х., Блинова Е.В., Сахнова Т.А., др. Изменения электро- кардиограммы в 12 отведениях у больных с идиопатической ле- гочной гипертензией. Медицинский алфавит. 2018;4(36):29-35. [Alokova F.Kh., Blinova E.V., Sakhnova T.A., et al. Changes of the electrocardiogram in 12 leads in patients with idiopathic pulmonary hypertension. Medical alphabet. 2018;4(36):29-35. (In Russ.)]
  71. Klok FA, Surie S, Kempf T, et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011;128:21-26. https://doi.org/10.1016/j.thromres.2011.03.004
  72. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132. https://doi. org/10.1016/j.ahj.2006.09.008
  73. Kamphuis VP, Haeck ML, Wagner GS, et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol 2014; 47(2):175-
  74. 182. https://doi.org/10.1016/j.jelectrocard.2013.10.010
  75. Сахнова Т.А., Блинова Е.В., Белевская А.А., др. Сопоставление интегральных показателей векторкардиограммы с данными эхо- кардиографического исследования у больных идиопатической и хронической тромбоэмболической лёгочной гипертензией. Тера- певтический архив 2019;3:11-16. https://doi.org/10.26442/0040366 0.2019.03.000043
  76. [Sakhnova TA, Blinova EV, Belevskaya AA, et al. Comparison of the integral indices of the vectorcardiogram with the data of echocardiography in patients with idiopathic and chronic thromboembolic pulmonary hypertension. Terapevticheskii arkhiv 2019;91(3):11-16. (in Russ.) https://doi.org/10.26442/00403660.201
  77. 9.03.000043]
  78. Remy-Jardin M, Ryerson CJ, Schiebler ML, et al. Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. Eur Respir J 2021;57:2004455. https://doi.org/10.1183/13993003.04455- 2020
  79. Коробкова И.З., Лазуткина В.К., Низовцова Л.А., Ридэн Т.В. Мето- дические аспекты рентгенологической оценки лёгочной гипертен- зии. ВРР 2015;4:45-53. https://doi.org/10.20862/0042-4676-2015-0- 4-14-21
  80. [Korobkova I.K., Lazutkina V.K., Nizovtsova L.A., Riden T.V. Radiographic assessment of pulmonary hypertension: Methodical aspects. Journal of radiology and nuclear medicine. 2015;(4):46-53. (In Russ.) https://doi.org/10.20862/0042-4676-2015-0-4-14-21]
  81. Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonaryhypertension. Ann Thorac Med 2017;12:61-73. https:// doi.org/10.4103/1817-1737.203742
  82. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41:1028- 1035. https://doi.org/10.1016/s0735-1097(02)02964-9
  83. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults:a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685–713. https://doi.org/10.1016/j. echo.2010.05.010
  84. Белевская А.А., Дадачева З.Х., Саидова М.А., др. Возможности эхокардиографии в диагностике лёгочной гипертензии и оценке ремоделирования сердца. Лечебное дело 2015;1:111-121. [Belevskaya A.A., Dadacheva Z.Kh., Saidova M.A., et al. The Role of Echocardiography in Diagnosis of Pulmonary Hypertension and Assessment of Heart Remodeling. General Medicine 2015;1:111-121. (in Russ.)]
  85. Rich JD, Shah SJ, Swamy RS et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139(5):988-993. https://doi.org/10.1378/chest.10-1269
  86. Finkelhor RS, Lewis SA, Pillai D. Limitations and strengths of doppler/ echo pulmonary artery systolic pressure-right heart catheterizationcorrelations: a systematic literature review. Echocardiography 2015;32(1):10-18. https://doi.org/10.1111/echo.12594
  87. Magnino C, Omede P, Avenatti E, et al. Inaccuracy of right atrial pressure estimates through inferior vena cava indices. Am J Cardiol 2017; 120 (9):1667-1673. https://doi.org/10.1016/j.amjcard.2017.07.069
  88. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6 (2):359-65. https://doi.org/10.1016/s0735-1097(85)80172-8
  89. Greiner S, Jud A, Aurich M et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc. 2014; 3(4): e001103. https://doi. org/10.1161/jaha.114.001103
  90. Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open 2019; 22;9(12):e033084. https://doi. org/10.1136/bmjopen-2019-033084
  91. Amsallem M, Sternbach JM, Adigopula S, et al. Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography. J Am Soc Echocardiogr 2016; 29 (2):93-102 https://doi.org/10.1016/j.echo.2015.11.001
  92. Willis J, Henry F, Wild C, et al. Echocardiographic probability of pulmonary hypertension: a real world audit comparing 2015 and 2022 ESC guidelines. Abstract presented at ESC Congress 2023. Eur Heart J 2023; Vol. 44, Issue Supplement_October 2023; in press.
  93. D'Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013;168(4):4058-62. https:// doi.org/10.1016/j.ijcard.2013.07.005
  94. Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2018; 72(22):2778- 2788. https://doi.org/10.1016/j.jacc.2018.08.2201
  95. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30(6):1527-33. https://doi.org/10.1016/s0735-1097(97)00344-6
  96. Todaro MC, Carerj S, Zito C, et al. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. Am J Cardiovasc Dis. 2020;10(4):272-283. PMID: 33224574
  97. Vizza CD, Lang IM, Badagliacca R, et al. Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension? Am J Respir Crit Care Med 2022; 205(7):751-760. https://doi.org/10.1164/rccm.202109-2079pp
  98. Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging 2016; 9 (6):733-46. https://doi.org/10.1016/j.jcmg.2016.02.022
  99. Wright L, Dwyer N, Wahi S, Marwick TH. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2103-2111. https://doi.org/10.1016/j. jcmg.2018.08.017
  100. Farmakis IT, Demerouti E, Karyofyllis P, et al. Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility? J Clin Med. 2021;10(13):2826. https://doi. org/10.3390/jcm10132826
  101. Restrepo CS, Carswell AP. Aneurysms and pseudoaneurysms of the pulmonary vasculature. Semin Ultrasound CT MR. 2012;33(6):552-66. https://doi.org/10.1053/j.sult.2012.04.001
  102. Berger T, Siepe M, Simon B, et al. Pulmonary artery diameter: means and normal limits-assessment by computed tomography angiography. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):637-644. https:// doi.org/10.1093/icvts/ivab308
  103. Reisenauer JS, Said SM, Schaff HV, et al. Outcome of Surgical Repair of Pulmonary Artery Aneurysms: A Single-Center Experience With 38 Patients. Ann Thorac Surg. 2017;104(5):1605-1610. https://doi. org/10.1016/j.athoracsur.2017.03.077
  104. Duijnhouwer AL, Navarese EP, Van Dijk AP, et al. Aneurysm of the Pulmonary Artery, a Systematic Review and Critical Analysis of Current Literature. Congenit Heart Dis. 2016;11(2):102-109. https:// doi.org/10.1111/chd.12316
  105. Алеевская А.М., Выборов О.Н., Грамович В.В., Мартынюк Т.В. Особенности дифференциальной диагностики тромбоза лёгоч- ной артерии у пациентов с лёгочной гипертензией (клиническое наблюдение). Пульмонология. 2019;29(5):620-624. https://doi. org/10.18093/0869-0189-2019-29-5-620-624
  106. [Aleevskaia A.M., Vyborov O.N., Gramovich V.V., Martynuk T.V. Diagnosis of pulmonary embolism in patients with pulmonary hypertension (a case report). Pulmonologiya. 2019;29(5):620-624. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-5-620-624]
  107. Mesquita SM, Castro CR, Ikari NM et al. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med. 2004 Mar 15;116(6):369-
  108. 74. https://doi.org/10.1016/j.amjmed.2003.11.015
  109. Galiè N, Saia F, Palazzini M, et al. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. J Am Coll Cardiol 2017; 69(23):2808-2817. https://doi. org/10.1016/j.jacc.2017.03.597
  110. Kreibich M, Siepe M, Kroll J et al. Aneurysms of the pulmonary artery. Circulation 2015;131(3):310-316. https://doi.org/10.1161/ circulationaha.114.012907
  111. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680–684. https://doi.org/10.2967/ jnumed.106.039438
  112. Архипова О.А., Мартынюк Т.В., Самойленко Л.Е., др. Перфузи- онная сцинтиграфия лёгких у больных с лёгочной гипертензией различной этиологии. Евразийский Кардиологический Журнал. 2015;(4):20-25. https://doi.org/10.38109/2225-1685-2015-4-20-25
  113. [Arkhipova O.A., Martynyuk T.V., Samoilenko L.E., et al. Perfusion lung scintigraphy in patients with a pulmonary hypertension of a various etiology. Eurasian heart journal. 2015;(4):20-25. (In Russ.) https://doi. org/10.38109/2225-1685-2015-4-20-25]
  114. Хроническая тромбоэмболическая лёгочная гипертензия: Руко- водство для врачей/ Под ред. Т.В. Мартынюк, акад. РАН И.Е. Чазо- вой. – Москва: ООО «Медицинское информационное агентство», 2023. 416 с. ISBN 978-5-907098-61-9
  115. [Chronic thromboembolic pulmonary hypertension: A guide for doctors / Ed. T.V. Martynyuk, acad. RAS I.E. Chazovoy. – Moscow: Medical Information Agency LLC, 2023. 416 p. (In Russ.) ISBN 978- 5-907098-61-9]
  116. Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/ perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019; 46:2429–2451. https://doi.org/10.1007/s00259-019-
  117. 04450-0
  118. Masy M, Giordano J, Petyt G, et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018; 28:5100–5110. https://doi. org/10.1007/s00330-018-5467-2
  119. Dissaux, B, Le Floch PY, Robin P, et al. Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). Eur Radiol 2020;30:4857–4864. https://doi.org/10.1007/s00330-020-06836-3
  120. Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging 2017; 46: 1693–1697. https:// doi.org/10.1002/jmri.25714
  121. Swift AJ, Dwivedi K, Johns C, et al. Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;30:4918–4929. https://doi.org/10.1007/s00330-020-
  122. 06846-1
  123. Dong C, Zhou M, Liu D, et al. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015;10:e0126985. https://doi.org/10.1371/journal.pone.0126985
  124. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung Transplant 2019;38:731–738. https://doi.org/10.1016/j. healun.2019.03.003
  125. Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014;112:598–605. https://doi.org/10.1160/th13-07-0538
  126. Tamura M, Yamada Y, Kawakami T, et al. Diagnostic accuracy of
  127. lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543. https://doi.org/10.1016/j.ijcard.2017.05.006
  128. Веселова Т.Н., Демченкова А.Ю., Ен М.Ю., др. Оценка перфузии лёгких у больных хронической тромбоэмболической легочной гипертензией методами компьютерной томографии и сцинтигра- фии. REJR. 2022;12(2):94-103. https://doi.org/10.21569/2222-7415- 2022-12-2-94-103
  129. [Veselova T.N., Demchenkova A.Yu., En M.Yu., et al. The assessment of lung perfusion in patients with chronic thromboembolic pulmonary hypertension using CT and scintigraphy. REJR 2022;12(2):94-103. (in Russ.) https://doi.org/10.21569/2222-7415-2022-12-2-94-103]
  130. Meyer GMB, Spilimbergo FB, Altmayer S, et al. Correction to: Multiparametric magnetic resonance imaging in the assessment of pulmonary hypertension: initial experience of a one-stop study. Lung 2018;196:497. https://doi.org/10.1007/s00408-018-0130-x
  131. Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson 2012; 14:40–50. https://doi.org/10.1186/1532-429x-14-40
  132. Hatabu H, Ohno Y, Gefter WB, et al. Expanding applications of pulmonary MRI in the clinical evaluation of lung disorders: Fleischner society position paper. Radiology 2020; 297(2): 286-301. https://doi. org/10.1148/radiol.2020201138
  133. Kiely DG, Levin D, Hassoun P, et al. EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).Pulm Circ. 2019; 9:2045894019841990. https://doi. org/10.1177/2045894019841990
  134. Van de Veerdonk MC, Marcus JT, Bogaard HJ, et al. State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series). Pulm Circ 2014;4(2):158–
  135. 168. https://doi.org/10.1086/675978
  136. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011; 20(122):243-
  137. 253. https://doi.org/10.1183/09059180.00006511
  138. Swift AJ, Wild JM, Nagle SK, et al. Quantitative magnetic resonance imaging of pulmonary hypertension a practical approach to the current state of the art. J Thorac Imag 2014; 29(2):68-79. https://doi. org/10.1097/rti.0000000000000079
  139. Simpson CE, Damico RL, Kolb TM, Mathai SC, Khair RM, Sato T, Bourji K, Tedford RJ, Zimmerman SL, Hassoun PM. Ventricular mass as a prognostic imaging biomarker in incident pulmonary arterial hypertension. Eur Respir J. 2019 Apr 4;53(4):1802067. https://doi. org/10.1183/13993003.02067-2018
  140. Johns CS, Kiely DG, Rajaram S, et al. Diagnosis of pulmonary hypertension with cardiac MRI: derivation and validation of regression models. Radiology. 2019;290:61–68. https://doi.org/10.1148/ radiol.2018180603
  141. Johns CS, Swift AJ, Hughes PJC, Ohno Y, Schiebler M, Wild JM. Pulmonary MR angiography and perfusion imaging-A review of methods and applications. Eur J Radiol. 2017 Jan;86:361-370. https:// doi.org/10.1016/j.ejrad.2016.10.003
  142. Rajaram S, Swift AJ, Capener D, et al. Diagnostic accuracy of contrast- enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012; 22:310–317. https://doi. org/10.1007/s00330-011-2252-x
  143. Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2020;29:S1936-878X(20)30731–2.  https://doi.org/10.1016/j. jcmg.2020.08.013
  144. Saunders LC, Johns CS, Stewart NJ, et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018;20:78. https://doi.org/10.1186/s12968-018-0501-8
  145. Maschke SK, Schoenfeld CO, Kaireit TF, et al. MRI-derived regional biventricular function in patients with chronic thromboembolic pulmonary hypertension before and after pulmonary endarterectomy. Acad Radiol. 2018;25:1540–1547. https://doi.org/10.1016/j. acra.2018.04.002
  146. Sieren MM, Berlin C, Oechtering TH, et al. Comparison of 4D flow MRI to 2D flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. PLoS One 201914(10):e0224121. https://doi.org/10.1371/journal.pone.0224121
  147. Saunders LC, Johns CS, Stewart NJ, Oram CJE, Capener DA, Puntmann VO, Elliot CA, Condliffe RC, Kiely DG, Graves MJ, Wild JM, Swift AJ. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018 Dec 3;20(1):78. https:// doi.org/10.1186/s12968-018-0501-8
  148. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. SwissMed Wkly 2003; 133:163–169. https://doi. org/10.4414/smw.2003.10016
  149. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141:678–693. https://doi.org/10.1161/ circulationaha.116.022362
  150. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–818. https://doi.org/10.1056/NEJMoa1213917
  151. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122:1668-1673. https://doi.org/10.1378/chest.122.5.1668
  152. Шмальц А.А. Динамика дистанции шестиминутной ходьбы как показатель эффективности специфических лёгочных вазо- дилататоров. Рациональная Фармакотерапия в Кардиологии. 2022;18(3):342-349. https://doi.org/10.20996/1819-6446-2022-06-09
  153. [Shmalts A.A. Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators. Rational Pharmacotherapy in Cardiology. 2022;18(3):342-349. (In Russ.) https://doi. org/10.20996/1819-6446-2022-06-09]
  154. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60(13): 1192–1201. https://doi.org/10.1016/j. jacc.2012.01.083
  155. Таран И.Н., Валиева З.С., Мартынюк Т.В., др. Вклад спировело- эргометрии в диагностический алгоритм обследования больных с лёгочной артериальной гипертензией. Медицинский алфавит. Больница (кардиология). 2016;3:19-23.
  156. [Taran I.N., Valieva Z.S., Martynyuk T.V., et al. Relevance of cardiopulmonary test in diagnostic algoritm in patients with pulmonary arterial hypertension. Medical alphabet. Hospital (cardiology). 2016;3:19-23. (in Russ.)]
  157. Sherman AE, Saggar R. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin 2023;19(1):35-43. https://doi.org/10.1016/j.hfc.2022.08.015
  158. Dumitrescu D, Nagel C, Kovacs G, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017; 103:774–782. https://doi.org/10.1136/ heartjnl-2016-309981
  159. Torres-Castro R, Gimeno-Santos E, Vilaró J, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.Eur Respir Review 2021; 30:200321. https://doi.org/10.1183/16000617.0321-2020
  160. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552. https:// doi.org/10.1016/j.jacc.2006.07.061
  161. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013;42:1586–1594. https://doi.org/10.1183/09031936.00050713
  162. Куропий Т.С., Данилов Н.М., Матчин Ю.Г. Сосудистые доступы к правым отделам сердца и легочным артериям: современное со- стояние вопроса. Кардиологический вестник 2022;17(3):23-28. https://doi.org/10.17116/Cardiobulletin20221703123
  163. [Kuropii TS, Danilov NM, Matchin YuG. Vascular accesses for right heart interventions: state of the art. Russian Cardiology Bulletin. 2022;17(3):23-28. (In Russ.) https://doi.org/10.17116/ Cardiobulletin20221703123]
  164. Шмальц А.А., Мартынюк Т.В., Наконечников С.Н. Расчет гемодина- мики методом Фика при лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Евразийский кардиологиче- ский журнал 2022;(2):96-102. https://doi.org/10.38109/2225-1685- 2022-2-96-102
  165. [Shmalts A.A., Martynyuk T.V., Nakonechnikov S.N. Calculation of hemodynamics by the Fick method in pulmonary hypertension associated with congenital heart defects. Eurasian heart journal. 2022;(2):96-102. (In Russ.) https://doi.org/10.38109/2225-1685- 2022-2-96-102]
  166. Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: an analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol. 2017; 2:1090–1099. https://doi.org/10.1001/jamacardio.2017.2945
  167. Viray MC, Bonno EL, Gabrielle ND, et al. Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail. 2020;13:e007981. https://doi. org/10.1161/circheartfailure.120.007981
  168. Kubiak GM, Ciarka A, Biniecka M, et al. Right heart catheterization – background, physiological basics, and clinical implications. J Clin Med 2019;8:1331. https://doi.org/10.3390/ jcm8091331
  169. Kaemmerer H, Apitz C, Brockmeier K, et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-
  170. 88. https://doi.org/10.1016/j.ijcard.2018.08.078
  171. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698-e800. https://doi.org/10.1161/cir.0000000000000603
  172. Xu Q, Yang Y, Geng J, et al. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension. Chin Med J (Engl) 2017;130(4):382-391. https://doi. org/10.4103/0366-6999.199829
  173. Yang Y, Yu Y, Yuan P, et al. Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Eur Clin Respir J 2020; 14(7):611-621. https://doi.org/10.1111/crj.13173
  174. Юрпольская Л.А., Шмальц А.А. Рентгенография, рентгеновская компьютерная и магнитно-резонансная томография при лёгочной гипертензии, ассоциированной с врождёнными пороками серд- ца. Детские болезни сердца и сосудов 2021; 18(2):83-93. https:// dx.doi.org/10.24022/1810-0686-2021-18-2-83-93
  175. [Yurpol’skaya L.A., Shmalts A.A. Х-ray methods and magnetic resonance imaging in pulmonary hypertension associated with congenital heart disease. Children’s Heart and Vascular Diseases. 2021; 18(2):83–93 (in Russ.). https://dx.doi.org/10.24022/1810-
  176. 0686-2021-18-2-83-93]
  177. Shimokawahara H, Ogawa A, Mizoguchi H, et al. Vessel stretching is a cause of lumen enlargement immediately after balloon pulmonary angioplasty: intravascular ultrasound analysis in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e006010. https://doi.org/10.1161/ circinterventions.117.006010
  178. Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019;28:190023. https://doi.org/10.1183/16000617.0023-2019
  179. Morrisroe K, Huq M, Stevens W, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med. 2016;16:134. https://doi.org/10.1186/s12890-016-0296-z
  180. Волков А.В., Мартынюк Т.В. Лёгочная артериальная гипертензия при системных заболеваниях соединительной ткани: современ- ное состояние проблемы. Научно-практическая ревматология 2018;56(4):474−485. https://doi.org/10.14412/1995-4484-2018-474-485
  181. [Volkov A.V., Martynyuk T.V. Pulmonary arterial hypertension in systemic connective tissue diseases: the current state of the problem. Rheumatology Science and Practice. 2018;56(4):474-485. (In Russ.) https://doi.org/10.14412/1995-4484-2018-474-485]
  182. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–3800. https://doi.org/10.1002/art.21433
  183. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522–3530. https://doi.org/10.1002/art.30541
  184. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:the DETECT study. Ann Rheum Dis. 2014;73:1340–134. https://doi.org/10.1136/ annrheumdis-2013-203301Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:1801899. https://doi.org/10.1183/13993003.01899-2018
  185. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21:K9–K20. https://doi. org/10.1093/eurheartj/suz204
  186. Boon G, Ende-Verhaar YM, Bavalia R, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax 2021;76:1002– 1009. https://doi.org/10.1136/thoraxjnl-2020-216324
  187. Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181. https://doi. org/10.1093/eurheartj/ehx257
  188. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50:1700740. https://doi.org/10.1183/13993003.00740-2017
  189. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50:1700889. https://doi.org/10.1183/13993003.00889-2017
  190. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159: 337–346. https://doi.org/10.1016/j.chest.2020.08.2069
  191. Zelniker TA, Huscher D, Vonk-Noordegraaf A, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 2018;107(6):460-70. https://doi. org/10.1007/s00392-018-1207-5
  192. Provencher S, Chemla D, Herve P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir
  193. J. 2006;27:114–120. https://doi.org/10.1183/09031936.06.00042705
  194. Khirfan G, Naal T, Abuhalimeh B, et al. Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One. 2018;13: e0191869. https://doi.org/10.1371/journal.pone.0191869
  195. Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transpl. 2020;39:300–309. https://doi.org/10.1016/j. healun.2019.12.013
  196. Nickel N, Golpon H, Greer M, et. al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 39:589–596. https://doi. org/10.1183/09031936.00092311
  197. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015; 34(3):362–368. https://doi. org/10.1016/j.healun.2014.08.020
  198. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013; 8(9):e72013. https://doi.org/10.1371/journal.pone.0072013
  199. Schiebler ML, Bhalla S, Runo J, et al. Magnetic resonance and computed tomography imaging of the structural and functional changes of pulmonary arterial hypertension. J Thorac Imaging. 2013; 28(3):178–193. https://doi.org/10.1097/rti.0b013e31828d5c48
  200. de Siqueira MEM, Pozo E, Fernandes VR, et al. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2016;18(1):39. https:// doi.org/10.1186/s12968-016-0258-x
  201. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131(2):402–409. https://doi. org/10.1378/chest.06-1758
  202. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482- 1489. https://doi.org/10.1161/circulationaha.106.618397
  203. Grunig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295. https://doi.org/10.1093/eurheartj/ehaa696
  204. Morris N.R., Kermeen F.D., Holland A.E. Exercise-basedrehabilitation programs for pulmonary hypertension. Cochrane Database of Systematic Reviews. 2017;1(1):CD011285. https://doi. org/10.1002/14651858.cd011285.pub2Chia KSW., Wong PKK., Faux SG. et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J 2017; 47(4):361–369. https://doi.org/10.1111/imj.13159
  205. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. https://doi. org/10.1093/eurheartj/ehac270
  206. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Россий- ский кардиологический журнал 2018, 3(155):91–134. https://doi. org/10.15829/1560-4071-2018-3-91-134
  207. [Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018;(3):91-
  208. 134. (In Russ.) https://doi.org/10.15829/1560-4071-2018-3-91-134]
  209. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165–3241. https://doi.org/10.1093/ eurheartj/ehy340
  210. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015; 5:435-465. https://doi.org/10.1086/682230
  211. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013;143:1330–1336. https://doi.org/10.1378/ chest.12-0528
  212. Hill W., Holy R., Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ. 2018;10(4):2045894018785259. https://doi. org/10.1177/2045894018785259
  213. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013; 29:1–14. https://doi.org/10.3109/0951359
  214. 0.2013.774591
  215. Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41:1302–1307. https://doi. org/10.1183/09031936.00089212
  216. Thangamathesvaran L, Armenia SJ, Merchant AM. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. Updates Surg. 2018 Dec;70(4):521-528. https://doi. org/10.1007/s13304-018-0556-y
  217. Чазова И.Е, Мартынюк Т.В, Валиева З.С, др. Оценка бремени хро- нической тромбоэмболической лёгочной гипертензии в Россий- ской Федерации. Терапевтический архив. 2018; 9: 101-109. https:// doi.org/10.26442/terarkh2018909101-109
  218. [Chazova IE, Martynyuk TV, Valieva ZS, et al. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Terapevticheskii arkhiv 2018;90(9):101-109. (In Russ.) https://doi.org/10.26442/terarkh2018909101-109]
  219. Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res. 2020;196:251–
  220. 256. https://doi.org/10.1016/j.thromres.2020.08.024
  221. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129:57–65. https://doi. org/10.1161/circulationaha.113.004526
  222. Грацианская С.Е., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Проблемные аспекты применения оральных антикоагулянтов у пациентов с легочной артериальной гипертензией различного ге- неза. Евразийский Кардиологический Журнал. 2017;(4):122-132. https://doi.org/10.38109/2225-1685-2017-4-122-132
  223. [Gratsianskaya S.Ye., Martynyuk T.V., Nakonechnikov S.N., Chazova I.Ye. Oral anticoagulants in patients with different forms of pulmonary arterial hypertension, aspects of the problem. Eurasian heart journal. 2017;(4):122-132. (in Russ.) https://doi.org/10.38109/2225-1685-
  224. 2017-4-122-132]
  225. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., соавт. Клинические ре- комендации по диагностике и лечению хронической тромбоэмбо- лической лёгочной гипертензии. (2 ЧАСТЬ). Терапевтический архив 2016; 88(10):63-73. https://doi.org/10.17116/terarkh201688663-73 [Chazova I.E., Martynyuk T.V., Filippov E.V., et al. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2). Terapevticheskii arkhiv 2016;88(10):63-73. (In Russ.) https://doi.org/10.17116/terarkh201688663-73]
  226. Mancuso L, Scordato F, Pieri M, et al. Management of portopulmonary hypertension: new perspectives. World J Gastroenterol. 2013;19:8252– 8257. https://doi.org/10.3748/wjg.v19.i45.8252
  227. Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education 2017; 17(7):228–234. https://doi. org/10.1093/bjaed/mkw074
  228. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21:K46– K53. https://doi.org/10.1093/eurheartj/suz207
  229. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792. https://doi.org/10.1378/ chest.114.3.787
  230. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132. https://doi. org/10.1016/j.ahj.2006.09.008
  231. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 2013; 167:2300–2305. https://doi.org/10.1016/j.ijcard.2012.06.024
  232. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53:1801906. https://doi. org/10.1183/13993003.01906-2018
  233. Jentzer JC, Mathier, MA. Pulmonary Hypertension in the Intensive Care Unit J Intensive Care Med 2016; 31(6):369–385. https://doi. org/10.1177/0885066615583652
  234. Sztrymf B, Souza R, Bertoletti I, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35:1286–1293. https://doi.org/10.1183/09031936.00070209
  235. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81. https://doi.org/10.1056/ nejm199207093270203
  236. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp Pharmacol. 2013;218:199–227. https://doi. org/10.1007/978-3-642-38664-0_9
  237. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and
  238. 2. Circulation. 2008; 117:3010–3019. https://doi.org/10.1161/ circulationaha.107.742510
  239. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903. https://doi. org/10.1056/nejmoa012212
  240. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–344. https://doi.org/10.1183/09031936.00138706
  241. Sitbon J, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2019; 7(7):594-604. https://doi.org/10.1016/s2213-2600(19)30091-8
  242. Galie N, Ghofrani HA, Torbicki A, et al, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148– 2157. https://doi.org/10.1056/nejmoa050010
  243. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069. https://doi.org/10.1161/01. cir.0000099502.17776.c2
  244. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–2903. https://doi.org/10.1161/circulationaha.108.839274
  245. Lichtblau, M., Harzheim, D., Ehlken, N., et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung 193; 1:105–112. https://doi.org/10.1007/s00408-014-9657-7
  246. Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavi combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011;51:1071–1078. https://doi. org/10.1177/0091270010379808
  247. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011;20:567–576. https://doi.org/10.1517/13543784.2011.565048
  248. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013;369:330-40. https://doi.org/10.1056/nejmoa1209655
  249. Ghofrani HA, D’Armini AM, Grimminger F, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-329. https://doi. org/10.1056/nejmoa1209657
  250. Ghofrani H-A, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomized, long- term extension trial. Lancet Respir Med. 2016; 4:361–371. https://doi. org/10.1016/s2213-2600(16)30019-4
  251. Simonneau G, D’Armini AM, Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015;45(5):1293-
  252. 302. https://doi.org/10.1183/09031936.00087114
  253. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009; 18(111):29–34. https://doi. org/10.1183/09059180.00011111
  254. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263. https://doi.org/10.1164/rccm.200603-358oc
  255. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694. https://doi.org/10.1183/09031936.06. 00057906
  256. Мартынюк Т.В. Оценка приверженности пациентов с лёгочной гипертензией лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового неинтервенционного ис- следования IVENT. Системные гипертензии. 2019;16(2):12-27. https://doi.org/10.26442/2075082X.2019.2.190352
  257. [Martynyuk TV. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension 2019;16(2):12-27. (in Russ.) https://doi.org/10.26442/ 2075082X.2019.2.190352]
  258. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533. https://doi.org/10.1056/nejmoa1503184
  259. Резухина Е.А., Родненков О.В., Мартынюк Т.В. Портрет типичного пациента с лёгочной артериальной гипертензией для назначе- ния агониста простациклиновых рецепторов селексипага. Евра- зийский Кардиологический Журнал 2023;(1):94-99. https://doi. org/10.38109/2225-1685-2023-1-94-99
  260. [Rezukhina E.A., Rodnenkov O.V., Martynyuk T.V. Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation. Eurasian heart journal. 2023;(1):94-99. (In Russ.) https://doi. org/10.38109/2225-1685-2023-1-94-99]
  261. Boucly A, Savale, L, Jaïs, X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J of Respir and Crit Care Med. 2021; 204(7):842–854. https://doi. org/10.1164/rccm.202009-3698oc
  262. Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:37–45. https:// doi.org/10.1016/j.ijcard.2018.08.082
  263. Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomized, controlled AMBITION study. Lancet Respir Med 2016;4:894–901. https://doi.org/10.1016/S2213-2600(16)30307-1
  264. McLaughlin VV, Vachiery, JL, Oudiz, RJ, et al. (AMBITION Study Group). Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J of Heart and Lung transplantation: the official publication of the International Society for Heart Transplantation. 2019; 38(12):1286–1295. https:// doi.org/10.1016/j.healun.2019.09.010 Lang I M, Palazzini, M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21(Suppl K):K21–K28. https://doi.org/10.1093/eurheartj/suz205
  265. Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной комбинированной специфической терапии лёгочной артериальной гипертензии в Российской Федерации. Терапевти- ческий архив 2020; 92(12):80-85. https://doi.org/10.26442/00403660.2020.12.000840 [Shmalts AA, Gorbachevsky SV. Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia. Terapevticheskii arkhiv 2020;92(12):80-85. (in Russ.) https:// doi.org/10.26442/00403660.2020.12.000840]
  266. Ляпина И.Н., Зверева Т.Н., Мартынюк Т.В. Возможности комбини- рованной терапии в лечении пациентов с впервые установленным диагнозом лёгочной артериальной гипертензии промежуточного риска. Consilium Medicum 2022; 24(10):688-695. https://doi.org/10. 26442/20751753.2022.10.201875
  267. [Lyapina IN, Zvereva TN, Martynyuk TV. Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. Consilium Medicum. 2022;24(10):688–695. (in Russ.) https:// doi.org/10.26442/20751753.2022.10.201875]
  268. Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834–844. https://doi.org/10.1056/nejmoa1413687
  269. Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102– 1110. https://doi.org/10.1164/rccm.201507-1398oc
  270. Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J;56(3):2000673. https://doi.org/10.1183/13993003.00673-2020
  271. Macitentan/Tadalafil Fixed-Dose Combination in Pulmonary Arterial Hypertension - A DUE. Presented by Dr. Kelly Chin at the American College of Cardiology Annual Scientific Session (ACC.23/WCC), New Orleans, LA, March 6, 2023. https://www.acc.org/Latest-in-Cardiology/ Clinical-Trials/2023/03/01/23/47/a-due
  272. Chin KM, Sitbon O, Doelberg M, et al. Three versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 2021;78:1393–1403. https://doi.org/10.1016/j. jacc.2021.07.057
  273. Thakrar MV, Weatherald JC, Varughese RA, et al. Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study. J Heart Lung Transplant. 2018;37(4S):S53-S54. https://doi.org/10.1016/j.healun.2018.01.115
  274. Satoshi A, Yoshihiro D, Kaori I, et al. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) – Protocol of a Multicenter Randomized Control Trial. Circ Rep. 2021;3(2):105-109. https://doi.org/10.1253/ circrep.cr-20-0133
  275. Gaine S, Sitbon O, Channick RN, et al. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest 2021; 160(1):277–
  276. 286. https://doi.org/10.1016/j.chest.2021.01.066
  277. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46(2):405-413. https://doi. org/10.1183/13993003.02044-2014
  278. Galiè, N. Gaine S, Channick R, et al. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in therapy 2022; 39(1):796-810. https://doi.org/10.1007/ s12325-021-01898-1
  279. Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50(3):1602425. https://doi.org/10.1183/13993003.02425-2016
  280. Taran IN, Belevskaya AA, Saidova MA, et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung 2018; 196(6):745-753. https://doi.org/10.1007/s00408-018-0160-4
  281. Мартынюк Т.В., Шмальц А.А., Горбачевский С.В., Чазова И.Е. Оп- тимизация специфической терапии лёгочной гипертензии: воз- можности риоцигуата. Терапевтический архив 2021; 93(9):1117– 1124. https://doi.org/10.26442/00403660.2021.09.201014 [Martynyuk TV, Shmalts AA, Gorbachevsky SV, Chazova IE. Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. Terapevticheskii arkhiv 2021;93(9):1117- 1124. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201014]
  282. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Новые горизонты применения антагониста рецепторов эндотелина второго поколе- ния мацитентана у пациентов с лёгочной гипертензией. Терапев- тический архив 2018; 2018:72-80. https://ter-arkhiv.ru/0040-3660/ article/view/32480 [Martynyuk TV, Nakonechnikov SN, Chazova IY. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension. Terapevticheskii arkhiv 2018;90(4):72-80. (in Russ.) https://ter-arkhiv.ru/0040-3660/ article/view/32480] Hoeper, MM, Al-Hiti, H, Benza, RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet Respir Med 2021; 9(6)573–584. https://doi.org/10.1016/s2213-2600(20)30532-4
  283. Чазова И.Е., Мартынюк Т.В. от имени авторов. Резолюция эксперт- ного совета по проблеме лёгочной артериальной гипертензии «Ме- няя парадигму лечения пациентов с ЛАГ». Терапевтический архив 2019;91(3):114-116. https://doi.org/10.26442/00403660.2019.03.000185 [Chazova IE, Martynyuk T.V. on behalf of the authors. Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension". Terapevticheskii arkhiv 2019;91(3):114-116. (in Russ.). https://doi.or g/10.26442/00403660.2019.03.000185] Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. Front Cardiovasc Med 2022;9:977110. https://doi.org/10.3389/fcvm.2022.977110 Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. J Cardiol. 2015; 66(4):304-314. https://doi.org/10.1016/j.jjcc.2015.02.001 SV, Shmalts AA, Dadabaev GM, et al. Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics (Basel). 2020;10(9):725. https://doi.org/10.3390/ diagnostics10090725
  284. Горбачевский С.В., Пурсанов М.Г., Шмальц А.А., др. Результаты атриосептостомии со стентированием у больных с идиопатиче- ской и схожими формами лёгочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019; 61(2):100-113. https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113 [Gorbachevsky S.V., Pursanov M.G., Shmalts A.A., et al. Results of stent fenestration of the interatrial septum in patients with idiopathic and similar forms of pulmonary arterial hypertension. Russian Journal of Thoracic and Cardiovascular Surgery. 2019;61(2):100–13 (in Russ.). https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113]
  285. Шмальц А.А., Нишонов Н.А. Атриосептостомия у больных с лё- гочной гипертензией. Грудная и сердечно-сосудистая хирургия. 2015;57(5):18-25. [Shmal’ts A.A., Nishonov N.A. Atrial septostomy for patients with pulmonary hypertension; Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2015;57(5):18-25. (in Russ.)]
  286. Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2019; 156:53–63. https:// doi.org/10.1016/j.chest.2019.03.003 Bartolome SD., Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016; 21(3):347–356. https://doi. org/10.1007/s10741-016-9562-7 Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53:1801906. https://doi. org/10.1183/13993003.01906-2018
  287. Шмальц А.А., Горбачевский С.В., Мартынюк Т.В., Наконечников С.Н. Тест на вазореактивность при лёгочной гипертензии, ассоциирован- ной с врождёнными пороками сердца. Евразийский кардиологиче- ский журнал 2022; 3:58-64. https://doi.org/10.38109/2225-1685-2022-
  288. 3-58-64 [Shmalts A.A., Gorbachevsky S.V., Martynyuk T.V., Nakonechnikov S.N. Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease. Eurasian heart journal. 2022;(3):58-64. (In Russ.) https://doi.org/10.38109/2225-1685-2022-3-58-64]
  289. Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Лёгочная гипер- тензия у детей с врождёнными пороками сердца. М.: ООО «Кедр»; 2018. ISBN 978-5-91487-115-1
  290. [Gorbachevsky S.V., Shmalts A.A., Plotnikova L.R. Pulmonary hypertension in children with congenital heart defects. M.: Kedr LLC; 2018. (In Russ.). ISBN 978-5-91487-115-1]
  291. Барышникова И.Ю., Шмальц А.А. Диагностика лёгочной гипертен- зии, ассоциированной с врождёнными пороками сердца. Часть 2. Эхокардиография. Российский вестник перинатологии и педиа- трии 2021;66:(6):23–32. https://doi.org/10.21508/1027-4065-2021-
  292. 66-6-23-32
  293. [Baryshnikova I.Yu., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(6):23-32. (In Russ.). https:// doi.org/10.21508/1027-4065-2021-66-6-23-32]
  294. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42(6):563-645. https://doi.org/10.1093/eurheartj/ ehaa554
  295. Соболев А.В., Шмальц А.А. Эндоваскулярная диагностика лёгоч- ной гипертензии, ассоциированной с врождёнными пороками сердца. Часть 1. Катетеризация сердца и ангиокардиография. Эн- доваскулярная хирургия 2021; 8(3):263–71. https://doi.org/https:// doi.org/10.24183/2409-4080-2021-8-3-263-271
  296. [Sobolev A.V., Shmalts A.A. Endovascular diagnostics of pulmonary hypertension associated with congenital heart defects. Part 1. Cardiac catheterization and angiography. Russian journal of endovascular surgery. 2021;8(3):263-71. (In Russ.) https://doi.org/10.24183/2409- 4080-2021-8-3-263-271]
  297. Горбачевский С.В., Шмальц А.А. Первичное обследование. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной ги- пертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:20-34. ISBN: 978-5-7982-0450-2
  298. [Gorbachevsky S.V., Shmalts A.A. Primary examination. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:20-34. (In Russ.) ISBN: 978-5-7982- 0450-2]
  299. Барышникова И.Ю., Шмальц А.А. Эхокардиография. В кн.: Горба- чевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертен- зии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:35-52. ISBN: 978-5-7982-0450-2
  300. [Baryshnikova I.Yu., Shmalts A.A. Echocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:35-52. (In Russ.) ISBN: 978-5-7982-0450-2]
  301. Юрпольская Л.А., Шмальц А.А. Рентгеновская компьютерная и магнитно-резонансная томография. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врож- дённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева»
  302. МЗ РФ; 2023:53-67. ISBN: 978-5-7982-0450-2
  303. [Yurpolskaya L.A., Shmalts A.A. X-ray computed tomography and magnetic resonance imaging. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:53-67. (In Russ.) ISBN: 978-5-7982-0450-2]
  304. Соболев А.В., Шмальц А.А. Катетeризация сердца и ангиокардио- графия. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ
  305. «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:68-83. ISBN: 978-5- 7982-0450-2
  306. [Sobolev A.V., Shmalts A.A. Cardiac catheterization and angiocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:68-83. (In Russ.) ISBN: 978-5-7982-0450-2] 
  307. Глушко Л.А., Шмальц А.А. Оценка состояния кардиреспираторной системы. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагности- ка лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:109-124. ISBN: 978-5-7982-0450-2
  308. [Glushko L.A., Shmalts A.A. Assessment of the state of the cardiorespiratory system. In the book: Gorbachevsky S.V., Shmalts
  309. A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:109-124. (In Russ.) ISBN: 978-5-7982-0450-2]
  310. Шмальц А.А., Горбачевский С.В. Тест на вазореактивность. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной ги- пертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:99-108. ISBN: 978-5-7982-0450-2
  311. [Shmalts A.A., Gorbachevsky S.V. Vasoreactivity test. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:99-108. (In Russ.) ISBN: 978-5-7982- 0450-2]
  312. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ 2020;10:2045894020917885. https://doi.org/10.1177/2045894020917885
  313. Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфиче- ские легочные вазодилататоры после операции Фонтена. Дет- ские болезни сердца и сосудов 2017;14(1):16-24. https://dx.doi. org/10.24022/1810-0686-2017-14-1-16-24
  314. [Shmal’ts A.A., Belkina M.V., Gorbachevskiy S.V. Specific pulmonary vasodilators after Fontan operation. Detskie bolezni serdtsa i sosudov (Children's Heart and Vascular Diseases). 2017;14(1):16–24 (in Russ.) https://dx.doi.org/10.24022/1810-0686-2017-14-1-16-24]
  315. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48–54. https://doi. org/10.1161/circulationaha.106.630715
  316. Шмальц А.А., Горбачевский С.В. Доказательная база специфи- ческих лёгочных вазодилататоров у взрослых с врождёнными пороками сердца. Терапевтический архив. 2021;93(9):1106-1116. https://doi.org/10.26442/00403660.2021.09.201022
  317. [Shmalts AA, Gorbachevsky SV. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii arkhiv 2021;93(9):1106-1116. (In Russ.) https://doi.org/10.26442/00 403660.2021.09.201022]
  318. Rubio-Rivas M, Royo C, Simeón CP, et al.. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-19. https://doi.org/10.1016/j. semarthrit.2014.05.010
  319. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8-18. https://doi.org/10.1183/09059180.00008211
  320. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. https://doi.org/10.1164/rccm.200510-1668oc
  321. Гусева, Н.Г. Системная склеродермия – мультидисциплинарная проблема. Научно-практическая ревматология 2011;49(2):10-14. https://doi.org/10.14412/1995-4484-2011-596
  322. [Guseva N.G., Guseva H.G. Systemic scleroderma is a multidisciplinary problem. Rheumatology Science and Practice. 2011;49(2):10-14. (In Russ.) https://doi.org/10.14412/1995-4484-2011-596]
  323. Волков А.В., Мартынюк Т.В., Юдкина Н.Н. и др. Выживаемость пациентов с лёгочной артериальной гипертонией, ассоцииро- ванной с системной склеродермией. Терапевтический архив 2012;84(5):24-28. https://ter-arkhiv.ru/0040-3660/article/view/31020 [Volkov AV, Martynyuk TV, Yudkina NN, et al. Survival of patients with pulmonary arterial hypertension, associated with systemic sclerosis. Terapevticheskii arkhiv 2012;84(5):24-28. (In Russ.) https://ter-arkhiv. ru/0040-3660/article/view/31020]
  324. Attanasio U, Cuomo A, Pirozzi F, et al. Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. Int J Mol Sci. 2020;21(12):4430. https://doi.org/10.3390/ ijms21124430
  325. Николаева Е.В., Корсакова Ю.О., Курмуков И.А. и др. Возможно- сти эхокардиографического определения давления в лёгочной артерии у пациентов с системными заболеваниями соедини- тельной ткани: данные ревматологического экспертного центра. Научно-практическая ревматология 2015;53(1):51-57. https://doi. org/10.14412/1995-4484-2015-51-57 [Nikolaeva E.V., Korsakova Yu.O., Kurmukov I.A., et al. Possibilities for echocardiographic determination of pulmonary artery pressure in patients with systemic connective tissue diseases: data of a rheumatology expert center. Rheumatology Science and Practice. 2015;53(1):51-57. (In Russ.) https://doi.org/10.14412/1995-4484-2015-51-57]
  326. Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В., Волков А.В. Клини- ческий субтип системной склеродермии, ассоциированный с лё- гочной артериальной гипертензией. Кардиологический вестник. 2017;12(4):66-75. [Yudkina N.N., Nikolaeva E.V., Martynyuk T.V., Volkov A.V. The clinical subtype of systemic scleroderma associated with pulmonary arterial hypertension. Kardiologicheskiy vestnik (Cardiological Bulletin). 2017;4:66–75. (in Russ.)]
  327. Simpson CE, Damico RL, Hummers L, et al. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis- related pulmonary arterial hypertension. Pulm Circ. 2019;9(3): 2045894019859477. https://doi.org/10.1177/2045894019859477
  328. Santos-Gomes J, Gandra I, Adão R, et al. An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Front Cardiovasc Med 2022;9:924873. https://doi.org/10.3389/fcvm.2022.924873
  329. Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2015;17(1):7. https://doi. org/10.1186/s13075-015-0517-5
  330. Savale L, Guimas M, Ebstein N, Fertin M, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139. https://doi.org/10.1016/j. jhep.2020.02.021
  331. Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version
  332. 10.0. HIV Med. 2020;21:617–624. https://doi.org/10.1111/hiv.12878
  333. Garry JD, Kolaitis NA, Kronmal R, et al. Pulmonary Hypertension Association Registry Investigators. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). J Heart Lung Transplant. 2022;41(12):1808-1818. https://doi. org/10.1016/j.healun.2022.08.019
  334. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40. https://doi.org/10.1097/01.aids.0000327514.60879.47
  335. Mularek-Kubzdela T, Ciurzyński M, Kowal Bielecka O, et al. An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease. Kardiol Pol. 2021;79(7-8):917-929. https://doi. org/10.33963/kp.a2021.0055
  336. Конева О.А., Овсянникова О.Б., Старовойтова М.Н., и др. Изо- лированное снижение диффузионной способности лёгких при системной склеродермии без лёгочной артериальной гипертен- зии: длительное проспективное наблюдение. Пульмонология. 2016;26(6):708-714. https://doi.org/10.18093/0869-0189-2016-26-
  337. 6-708-714
  338. [Koneva O.A., Ovsyannikova O.B., Starovoytova M.N., et al. Isolated decrease of the lung diffusing capacity in patients with systemic sclerosis without pulmonary arterial hypertension: a long-term prospective study. Pulmonologiya. 2016;26(6):708-714. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-6-708-714]
  339. Xanthouli P. Improved Survival for Patients with Systemic Sclerosis- associated Pulmonary Arterial Hypertension: For Real? Am J Respir Crit Care Med. 2023;207(3):238-240. https://doi.org/10.1164/ rccm.202210-2006ed
  340. Lazaro SM, Quezada Loaiza CA, Rodriguez Padial, et al. Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. Intern Med. 2021;51:355–365. https://doi.org/10.1111/imj.14751
  341. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012;141:906–915. https://doi.org/10.1378/chest.11-0160
  342. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212–1217. https://doi.org/10.1164/rccm.200404-445oc Certain MC, Chaumais MC, Jais X, et al. Characteristics and long- term outcomes of pulmonary venoocclusive disease induced by mitomycin C. Ches. 2021;159:1197–1207. https://doi.org/10.1016/j. chest.2020.09.238
  343. Montani D, Girerd B, Jais X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017;5:125–134. https:// doi.org/10.1016/s2213-2600(16)30438-6
  344. Меркулов Е.В., Сапельников О.В., Власова Э.Е., др. Осложнения катетерной абляции у пациента с фибрилляцией предсердий: стеноз всех лёгочных вен. Особенности эндоваскулярного ле- чения. Кардиология 2019;59(5):92-96. https://doi.org/10.18087/ cardio.2019.5.10260
  345. [Merkulov E.V., Sapelnikov O.V., Vlasova E.E., et al. Complications of the Catheter Treatment of Atrial Fibrillation: Stenosis of All Pulmonary Veins after Radiofrequency Ablation. Kardiologiia. 2019;59(5):92-96. (In Russ.) https://doi.org/10.18087/cardio.2019.5.10260]
  346. Assad TR, Hemnes AR, Larkin EK et al. Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. J Am Coll Cardiol 2016; 68(23):2525-2536. https://doi.org/10.1016/j. jacc.2016.09.942
  347. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009;136(1):37-43. https:// doi.org/10.1378/chest.08-2784
  348. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726. https://doi.org/10.1093/eurheartj/ ehab368
  349. Bermejo J, Gonzalez-Mansilla A, Mombiela T, et al. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc. 2021;10: e019949. https://doi.org/10.1161/jaha.120.019949
  350. Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50:1700578. https://doi.org/10.1183/13993003.00578- 2017
  351. D’Alto M, Romeo E, Argiento P, et al. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest. 2017;151:119–126. https://doi.org/10.1016/j.chest.2016.08.1439
  352. Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 2017;26:433–441. https://doi.org/10.1016/j.hlc.2016.09.004
  353. Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51:1701886. https://doi.org/10.1183/13993003.01886-2017
  354. Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018; 39:1255–1264. https://doi. org/10.1093/eurheartj/ehx700
  355. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonaryhypertension–a multi-center randomized study. Cardiology. 2008;109:273–280. https://doi.org/10.1159/000107791
  356. Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. Int J Cardiol 2018;273:213–220. https://doi.org/10.1016/j.ijcard.2018.09.043
  357. Lilly LS. Pathophysiology of Heart Disease: An Introduction to Cardiovascular Medicine (p. 249). Wolters Kluwer Health, 7 th. ed., 2021; Kindle Edition. ISBN-13: 978-1975120597
  358. Ляпина И.Н., Теплова Ю.Е., Мартынюк Т.В. Фенотип пациентов с лёгочной гипертензией вследствие патологии левых отделов сердца: особенности патофизиологии и дифференциальной диа- гностики. Комплексные проблемы сердечно-сосудистых забо- леваний 2022;11(4):118-129. https://doi.org/10.17802/2306-1278-
  359. 2022-11-4-118-129
  360. [Lyapina I. N., Teplova Yu. E., Martynyuk T. V. Phenotype of patients with pulmonary hypertension due to left heart disease: features of pathophysiology and differential diagnosis. Complex Issues of Cardiovascular Diseases. 2022;11(4):118-129. (In Russ.) https://doi. org/10.17802/2306-1278-2022-11-4-118-129] Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689–697. https://doi.org/10.1093/eurheartj/ehy809
  361. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555–
  362. 1562. https://doi.org/10.1161/circulationaha.107.716373
  363. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014; 16:444–453. https://doi.org/10.1002/ejhf.47
  364. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. https://doi.org/10.1016/j.jacc.2007.07.078
  365. Obokata M, Reddy YNV, Shah SJ, et al. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol 2019;74:2539–2550. https://doi. org/10.1016/j.jacc.2019.08.1062
  366. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011 Jul 12;124(2):164-174. https://doi.org/10.1161/ circulationaha.110.983866
  367. Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016; 68:368–378. https://doi. org/10.1016/j.jacc.2016.05.047
  368. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565–2573. https:// doi.org/10.1093/eurheartj/ehv336
  369. Dachs TM, Duca F, Rettl R, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 2022; 43(36):3402-3413. https://doi.org/10.1093/ eurheartj/ehac389
  370. Selim AM, Wadhwani L, Burdorf A, et al. Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019; 28(6):946-952. https://doi.org/10.1016/j.hlc.2018.04.299
  371. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose- ranging hemodynamic study. Circulation 2013; 128(5):502-11. https:// doi.org/10.1161/circulationaha.113.001458
  372. O’Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheteraortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 2015;8:e002358. https://doi.org/10.1161/ circinterventions.114.002358
  373. Tigges E, Blankenberg S, von Bardeleben RS, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018; 20:585–594. https://doi. org/10.1002/ejhf.864
  374. Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid- term outcomes. Heart 2012; 98:126–132. https://doi.org/10.1136/ heartjnl-2011-300705
  375. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561– 632. https://doi.org/10.1093/eurheartj/ehab395
  376. Schneider SR, Mayer LC, Lichtblau M, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomized crossover trial. ERJ Open Res 2021;7:00314-02021. https://doi.org/10.1183/23120541.00314-2021
  377. Groth A, Saxer S, Bader PR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018; 270:262–267. https://doi.org/10.1016/j.ijcard.2018.05.127
  378. Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100944. https://doi.org/10.1183/13993003.00944-202 Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393- 2399. https://doi.org/10.1378/chest.128.4.2393
  379. Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58: 2101483. https://doi.org/10.1183/13993003.01483-
  380. 2021
  381. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189–194. https://doi.org/10.1164/rccm.200401-006oc
  382. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752. https://doi.org/10.1378/ chest.129.3.746
  383. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531–1536. https://doi.org/10.1378/ chest.127.5.1531
  384. Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. Respirology. 2023; 28:262-72. https://doi.org/10.1111/resp.14378
  385. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158: 641–649. https://doi.org/10.7326/0003-4819-158-9-
  386. 201305070-00003
  387. Gou Q, Shi R, Zhang X, Meng Q, Li X, Rong X, Gawa Z, Zhuoma N, Chen X. The Prevalence and Risk Factors of High-Altitude Pulmonary Hypertension Among Native Tibetans in Sichuan Province, China. High Alt Med Biol. 2020;21(4):327-335. https://doi.org/10.1089/ ham.2020.0022
  388. Сарыбаев А.Ш., Сыдыков А.С., Сартмырзаева М.А., др. Высоко- горная лёгочная гипертония («болезнь Миррахимова»). Евра- зийский кардиологический журнал 2016;(4):76-83. https://doi. org/10.38109/2225-1685-2016-4-76-83
  389. [Sarybaev A.Sh., Sydykov A.S., Sartmyrzaeva M.A., et al. High altitude pulmonary hypertension («Mirrakhimov's disease»). Eurasian heart journal. 2016;(4):76-83. (In Russ.) https://doi.org/10.38109/2225- 1685-2016-4-76-83]
  390. Sime F, Penaloza D, Ruiz L. Bradycardia, increased cardiac output, and reversal of pulmonary hypertension in altitude natives living at sea level. Br Heart J. 1971;33:647-657. https://doi.org/10.1136/ hrt.33.5.647
  391. Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005;60:683- 687. https://doi.org/10.1136/thx.2005.041954
  392. Antezana AM, Antezana G, Aparicio O, et al. Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. Eur Respir J 1998;12:1181-1185. https://doi.org/10.1183/09031936.98.12051181
  393. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).Eur Heart J 2020;41:543–603. https://doi.org/10.1093/ eurheartj/ehz405
  394. Swietlik EM, Ruggiero A, Fletcher AJ, et al. Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 2019;53:1801787. https://doi. org/10.1183/13993003.01787-2018
  395. Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013 Aug 20;167(4):1193–1198. https://doi.org/10.1016/j.ijcard.2012.03.135
  396. Badagliacca R, Rischard F, Giudice FL, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790. https://doi.org/10.1016/j.healun.2022.02.021
  397. Jenkins DP, Biederman A, D"Armini AM, et al. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016;152(3):669–674. https://doi.org/10.1016/j.jtcvs.2016.02.062
  398. Чернявский А.М., Едемский А.Г., Новикова Н.В., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипертен- зии./ Национальный медицинский исследовательский центр име- ни Е.Н. Мешалкина; под общей редакцией А.М. Чернявского. — Новосибирск: НМИЦ: Издательство СО РАН, 2019.317 с. ISBN: 978-5-7692-1665-7 [Chernyavsky A.M., Edemsky A.G., Novikova N.V., et al. Surgical treatment of chronic thromboembolic pulmonary hypertension./ National Medical Research Center named after E.N. Meshalkina; under the general editorship of A.M. Chernyavsky. — Novosibirsk: National Medical Research Center: Publishing House SB RAS, 2019.317 p. (In Russ.) ISBN: 978-5-7692-1665-7]
  399. Araszkiewicz A, Darocha S, Pietrasik A, et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol. 2019;278: 232–237. https://doi.org/10.1016/j.ijcard.2018.10.066
  400. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103. https://doi.org/10.1016/j. athoracsur.2012.04.004
  401. Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2018;37:250–258. https://doi.org/10.1016/j.healun. 2017.06.011
  402. Акчурин Р.С., Мершин К.В., Табакьян Е.А., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипер- тензии: современные тенденции и собственный опыт. Евра- зийский Кардиологический Журнал. 2016; 2:40-47. https://doi. org/10.38109/2225-1685-2016-2-40-47
  403. [Akchurin R.S., Mershin K.V., Tabakyan E.A., et al. Surgical treatment of chronic thromboembolic pulmonary hypertension: modern trends and own experience. Eurasian heart journal. 2016;(2):40-47. (In Russ.) https://doi.org/10.38109/2225-1685-2016-2-40-47]
  404. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014;148:1005– 1011. https://doi.org/10.1016/j.jtcvs.2014.06.052
  405. Newnham M, Bunclark K, Abraham N, et al. CAMPHOR score: patient- reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2020;56:1902096. https://doi.org/10.1183/13993003.02096-2019
  406. Чернявский А.М., Едемский А.Г., Чернявский М.А., др. Пятилет- ние результаты хирургического лечения пациентов с хрониче- ской постэмболической лёгочной гипертензией Хирургия. Жур- нал им. Н.И. Пирогова. 2017;2:21-24. https://doi.org/10.17116/ hirurgia2017221-24
  407. [Cherniavskiĭ AM, Edemskiĭ AG, Cherniavskiĭ MA, et al. 5-year surgical results in patients with chronic postembolic pulmonary hypertension. Pirogov Russian Journal of Surgery = Khirurgiya. Zurnal im. N.I. Pirogova. 2017;(2):21-24. (In Russ.) https://doi.org/10.17116/ hirurgia2017221-24]
  408. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014;44:1635–1645. https://doi. org/10.1183/09031936.00050114
  409. Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018;52:1800589. https://doi.org/10.1183/13993003.00589- 2018
  410. Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961-971. https://doi.org/10.1016/s2213- 2600(22)00214-4
  411. Delcroix M, Staehler G, Gall H, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2018;52:1800248. https://doi.org/10.1183/13993003.00248- 2018
  412. Benza RL, Farber HW, Frost A, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018;37:836–843. https://doi.org/10.1016/j. healun.2018.02.015
  413. Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802004. https://doi. org/10.1183/13993003.02004-2018
  414. Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020;18:114–122. https://doi. org/10.1111/jth.14649
  415. Humbert MS, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2022;41:716–721. https://doi.org/10.1016/j. healun.2022.02.002
  416. Валиева З.С., Мартынюк Т.В. Выбор специфической и антикоагу- лянтной терапии у пациентов с впервые выявленной хронической тромбоэмболической легочной гипертензией в зависимости от статуса операбельности. Российский кардиологический журнал. 2023;28(3):5231. https://doi.org/10.15829/1560-4071-2023-5231
  417. [Valieva Z.S., Martynyuk T.V. Choice of specific and anticoagulant therapy in patients with newly diagnosed chronic thromboembolic pulmonary hypertension, depending on operability status. Russian Journal of Cardiology. 2023;28(3):5231. (In Russ.) https://doi. org/10.15829/1560-4071-2023-5231]
  418. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:685–694. https://doi. org/10.7326/m19-0291
  419. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high- risk patients with antiphospholipid syndrome. Blood 2018;132:1365– 1371. https://doi.org/10.1182/blood-2018-04-848333
  420. Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–794. https://doi.org/10.1016/s2213- 2600(17)30305-3
  421. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2010;139:85–91
  422. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hyper- tension. Eur Respir J. 2007;30:922–927. https://doi. org/10.1183/09031936.00039007
  423. Данилов Н.М., Матчин Ю.Г., Чазова И.Е., и др. Баллонная анги- опластика лёгочных артерий при неоперабельной хронической тромбоэмболической лёгочной гипертензии. Сonsilium Medicum 2016;5:59-61. https://consilium.orscience.ru/2075-1753/article/ view/94466
  424. [Danilov NM, Matchin YG, Chazova IE., et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Consilium Medicum 2016;18(5):59-61. (In Russ.) https://consilium.orscience.ru/2075-1753/article/view/94466]
  425. Mahmud E, Behnamfar O, Ang L,et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 2018;7:103–117. https://doi.org/10.1016/j.iccl.2017.09.003
  426. Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1222-1230. https://doi.org/10.1253/circj.cj-18-0258
  427. Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes. 2017;10:e004029. https://doi.org/10.1161/circoutcomes.117.004029
  428. Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ 2018; 8:2045894018783996. https://doi. org/10.1177/2045894018783996
  429. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394–1402. https://doi.org/10.1183/09031936.00012914
  430. Fukuda K, Hiroshi Date H, Doi S, et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019;83(4):842-945. https://doi.org/10.1253/circj.cj-66-0158
  431. Яровой С.Ю., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Структурные изменения легочных артерий после транслюминальной баллон- ной ангиопластики у пациентов с хронической тромбоэмболи- ческой легочной гипертензией. Евразийский Кардиологический Журнал. 2020;(4):12-20. https://doi.org/10.38109/2225-1685-2020- 4-12-20
  432. [Yarovoy S.Y., Danilov N.M., Matchin Yu.G., Chazova I.E. Structural changes of the pulmonary arteries after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Eurasian heart journal. 2020;(4):12-20. (In Russ.) https://doi. org/10.38109/2225-1685-2020-4-12-20 
  433. Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415–1420. https://doi. org/10.1136/heartjnl-2012-303549
  434. Kurzyna M, Darocha S, Pietura R, et al. Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. Kardiol Pol 2017;75:645–654. https://doi.org/10.5603/kp.a2017.0091
  435. Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017;49:1602409. https://doi.org/10.1183/13993003.02409-2016
  436. Godinas L, Bonne L, Budts W, et al. Balloon pulmonary angioplasty for the treatment of nonoperable chronic thromboembolic pulmonary hypertension: single-center experience with low initial complication rate. J Vasc Interv Radiol 2019;30:1265-1272. https://doi. org/10.1016/j.jvir.2019.03.023
  437. Lang IM, Andreassen AK, Andersen A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function. Eur Heart J 2023;44(29):2659-2671. https://doi.org/10.1093/eurheartj/ehad413
  438. Shinkura Y, Nakayama K, Yanaka K, et al. Extensive revascularisation by balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension beyond haemodynamic normalisation. EuroIntervention 2018;13:2060-2068. https://doi.org/10.4244/eij-d-17-00157
  439. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-833. https://doi.org/10.1056/nejmoa1501035
  440. Danilov NM, Matchin YuG, Sagaydak OV, et al. Antecubital vein access for balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: safe new approach. Russian Open Medical Journal 2019;8:e0107. https://doi.org/10.15275/ rusomj.2019.0107
  441. Данилов Н.М., Яровой С.Ю., Елфимова Е.М., др. Клинические и рентгенологические аспекты реперфузионного отёка лёгких по- сле транслюминальной баллонной ангиопластики лёгочных ар- терий у пациентов с хронической тромбоэмболической лёгочной гипертензией. Системные гипертензии. 2022;19(3):23-30. https:// doi.org/10.38109/2075-082X-2022-3-23-30
  442. [Danilov N.M., Yarovoy S.Yu., Elfimova E.M., Chazova IE., et al. Clinical and radiological aspects of reperfusion pulmonary edema after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2022;19(3):23-30. (In Russ.) https://doi.org/10.38109/2075-082X-2022-3-23-30]
  443. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009;120(13):1248-
  444. 54. https://doi.org/10.1161/circulationaha.109.865881
  445. Валиева З.С., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Характеристика пациентов с хронической тромбоэмболической лёгочной гипертензией по данным российского национального регистра. Терапевтический архив. 2021;93(9):1058-1065. https:// doi.org/10.26442/00403660.2021.09.201037
  446. [Valieva ZS, Martynyuk TV, Nakonechnikov SN, Chazova IE. Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii arkhiv. 2021;93(9):1058-1065. (in Russ.) https://doi. org/10.26442/00403660.2021.09.201037]
  447. Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open. 2019; 9(12):e033084. https://doi. org/10.1136/bmjopen-2019-033084
  448. Gall H, Yogeswaran A, Fuge J, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine. 2021;34:100822. https:// doi.org/10.1016/j.eclinm.2021.100822
  449. D'Alto M., Di Maio M., Romeo E, et al. Echocardiographic probability of pulmonary hypertension: a validation study. Eur Respir J 2022;60:2102548. https://doi.org/10.1183/13993003.02548-2021
  450. Sydykov A, Mamazhakypov A, Maripov A, et al. Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. Int J Environ Res Public Health. 2021;18(4):1692. https:// doi.org/10.3390/ijerph18041692 Soria R, Egger M, Scherrer U, et al. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta-analysis. J Appl Physiol 2016;121(5):1151- 1159. https://doi.org/10.1152/japplphysiol.00394.2016
  451. Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol. 2013;168(3):e89-e90. https://doi.org/10.1016/j. ijcard.2013.07.129
  452. Grover RF, Vogel JH, Voigt GC, et al. Reversal of high altitude pulmonary hypertension. Am J Cardiol 1966;18:928-932. https://doi. org/10.1016/0002-9149(66)90443-7
  453. Maripov A, Muratali Uulu K, Satybaldyev S, Kushubakova N, Sarybaev A. Reversal of pulmonary hypertension in a patient with chronic mountain sickness after relocation to low altitude. J Clin Diagn Res. 2021 y;15(5):OD09-OD10. http://dx.doi.org/10.7860/ JCDR/2021/48309.14886
  454. Singh I, Khanna PK, Lal M, et al. High-altitude pulmonary hypertension. Lancet.  1965;2(7404):146-50.  https://doi.org/10.1016/s0140-
  455. 6736(65)90229-1
  456. Richalet JP, Rivera-Ch M, Maignan M, et al. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med. 2008;177(12):1370-6. https://doi.org/10.1164/ rccm.200802-196oc
  457. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho- kinase inhibitor in patients with pulmonary arterial hypertension. Circ.
  458. J. Off. J. Jpn. Circ. Soc. 2006;70:174-178. https://doi.org/10.1253/ circj.70.174
  459. Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, et al. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur Respir
  460. J. 2012;39:496-498. https://doi.org/10.1183/09031936.00095211
  461. Sommer N, Ghofrani H-A, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178:6-30. https://doi.org/10.1111/bph.15016
  462. Grimminger F, Schermuly RT, Ghofrani H-A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9:956-970. https://doi.org/10.1038/nrd3297  
  463. дации по диагностике и лечению лёгочной гипертензии. Терапев- тический архив 2014;9:4–23.
  464. [Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskii Arkhiv. 2014;86(9):4-23 (In Russ.)]
  465. Минздрава России. ISBN 978-5-6040008-0-9
  466. [Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018. Series Library “National Medical Research Center of Cardiology” of the Ministry of Health of Russia (In Russ.). ISBN 978- 5-6040008-0-9]
  467. 1:78-122. https://doi.org/10.38109/2225-1685-2020-1-78-122
  468. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension (2019). Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi. org/10.38109/2225-1685-2020-1-78-122]
  469. [Chazova I.E., Martynyuk T.V. Pulmonary hypertension. – Moscow. Practice. 2015; 928 pp. (In Russ.)]
  470. [Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh. 2019 Mar 10;91(1):24-31. (in Russ.). https://doi.org/ 10.26442/00403660.2019.01.000024]
  471. [Chazova I.E., Gorbachevskij S.V., Martynyuk T.V., et al. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian heart journal. 2022;(2):6-70. (In Russ.). https://doi.org/10.38109/2225- 1685-2022-2-6-70] doi.org/10.1164/rccm.200704-541oc 54. https://doi.org/10.1093/eurheartj/ehv512
  472. [Martynyuk T.V. «Pulmonary hypertension due to pathology of the left heart». Chapter in the manual for doctors «Pulmonary hypertension», ed. Avdeeva S.N. (2nd edition). GEOTAR-MEDIA, Moscow, 2019. pp. 213-254 (in Russ.)]
  473. [Avdeev S.N., Barbarash O.L., Bautin A.E., et al. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.) https://doi. org/10.15829/1560-4071-2021-4683]
  474. [Nakonechnikov SN, Zykov KA, Martynyuk TV, et al. Profil' provospalitel'nykh markerov u patsientov s razlichnymi formami legochnoy gipertenzii. Systemic Hypertension 2010;7(3):61-66. (in Russ.) https://doi.org/10.26442/SG28888] [Bockeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart defects in adults. Methodological manual./ Bakulev Center for Cardiovascular Surgery, 2016. (in Russ.). ISBN: 978-5-7982-0368-0] [Chazova IE, Arkhipova OA, Valieva ZS, et al. Pulmonary hypertension in Russia: The first results of the national register. Terapevticheskii Arkhiv. 2014;86(9):56-64. (In Russ.)] 03660.2019.09.000343 [Chazova IE, Valieva ZS, Nakonechnikov SN, et al. Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry. Terapevticheskii arkhiv 2019;91(9):77-87. (in Russ.) https://doi.org/10.26442/0040366 0.2019.09.000343   ский Кардиологический Журнал. 2021;(1):6-43. https://doi. org/10.38109/2225-1685-2021-1-6-43
  475. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian heart journal. 2021;(1):6-43. (In Russ.) https://doi.org/10.38109/2225- 1685-2021-1-6-43] 182. https://doi.org/10.1016/j.jelectrocard.2013.10.010
  476. [Sakhnova TA, Blinova EV, Belevskaya AA, et al. Comparison of the integral indices of the vectorcardiogram with the data of echocardiography in patients with idiopathic and chronic thromboembolic pulmonary hypertension. Terapevticheskii arkhiv 2019;91(3):11-16. (in Russ.) https://doi.org/10.26442/00403660.201 9.03.000043]
  477. [Korobkova I.K., Lazutkina V.K., Nizovtsova L.A., Riden T.V. Radiographic assessment of pulmonary hypertension: Methodical aspects. Journal of radiology and nuclear medicine. 2015;(4):46-53. (In Russ.) https://doi.org/10.20862/0042-4676-2015-0-4-14-21]  correlations: a systematic literature review. Echocardiography 2015;32(1):10-18. https://doi.org/10.1111/echo.12594 наблюдение). Пульмонология. 2019;29(5):620-624. https://doi. org/10.18093/0869-0189-2019-29-5-620-624
  478. [Aleevskaia A.M., Vyborov O.N., Gramovich V.V., Martynuk T.V. Diagnosis of pulmonary embolism in patients with pulmonary hypertension (a case report). Pulmonologiya. 2019;29(5):620-624. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-5-620-624]
  479. 74. https://doi.org/10.1016/j.amjmed.2003.11.015
  480. [Arkhipova O.A., Martynyuk T.V., Samoilenko L.E., et al. Perfusion lung scintigraphy in patients with a pulmonary hypertension of a various etiology. Eurasian heart journal. 2015;(4):20-25. (In Russ.) https://doi. org/10.38109/2225-1685-2015-4-20-25]
  481. [Chronic thromboembolic pulmonary hypertension: A guide for doctors / Ed. T.V. Martynyuk, acad. RAS I.E. Chazovoy. – Moscow: Medical Information Agency LLC, 2023. 416 p. (In Russ.) ISBN 978- 5-907098-61-9] 04450-0 06846-1   lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543. https://doi.org/10.1016/j.ijcard.2017.05.006
  482. [Veselova T.N., Demchenkova A.Yu., En M.Yu., et al. The assessment of lung perfusion in patients with chronic thromboembolic pulmonary hypertension using CT and scintigraphy. REJR 2022;12(2):94-103. (in Russ.) https://doi.org/10.21569/2222-7415-2022-12-2-94-103] 168. https://doi.org/10.1086/67597253. https://doi.org/10.1183/09059180.00006511 14(10):e0224121. https://doi.org/10.1371/journal.pone.0224121
  483. [Shmalts A.A. Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators. Rational Pharmacotherapy in Cardiology. 2022;18(3):342-349. (In Russ.) https://doi. org/10.20996/1819-6446-2022-06-09]
  484. [Taran I.N., Valieva Z.S., Martynyuk T.V., et al. Relevance of cardiopulmonary test in diagnostic algoritm in patients with pulmonary arterial hypertension. Medical alphabet. Hospital (cardiology). 2016;3:19-23. (in Russ.)]
  485. [Kuropii TS, Danilov NM, Matchin YuG. Vascular accesses for right heart interventions: state of the art. Russian Cardiology Bulletin. 2022;17(3):23-28. (In Russ.) https://doi.org/10.17116/ Cardiobulletin20221703123]
  486. [Shmalts A.A., Martynyuk T.V., Nakonechnikov S.N. Calculation of hemodynamics by the Fick method in pulmonary hypertension associated with congenital heart defects. Eurasian heart journal. 2022;(2):96-102. (In Russ.) https://doi.org/10.38109/2225-1685-2022-2-96-102] 88. https://doi.org/10.1016/j.ijcard.2018.08.078
  487. [Yurpol’skaya L.A., Shmalts A.A. Х-ray methods and magnetic resonance imaging in pulmonary hypertension associated with congenital heart disease. Children’s Heart and Vascular Diseases. 2021; 18(2):83–93 (in Russ.). https://dx.doi.org/10.24022/1810-
  488. 0686-2021-18-2-83-93]
  489. [Volkov A.V., Martynyuk T.V. Pulmonary arterial hypertension in systemic connective tissue diseases: the current state of the problem. Rheumatology Science and Practice. 2018;56(4):474-485. (In Russ.) https://doi.org/10.14412/1995-4484-2018-474-485] 2017 J. 2006;27:114–120. https://doi.org/10.1183/09031936.06.00042705 rehabilitation programs for pulmonary hypertension. Cochrane Database of Systematic Reviews. 2017;1(1):CD011285. https://doi. org/10.1002/14651858.cd011285.pub2
  490. [Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018;(3):91- 134. (In Russ.) https://doi.org/10.15829/1560-4071-2018-3-91-134] 0.2013.774591
  491. [Chazova IE, Martynyuk TV, Valieva ZS, et al. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Terapevticheskii arkhiv 2018;90(9):101-109. (In Russ.) https://doi.org/10.26442/terarkh2018909101-109] 256. https://doi.org/10.1016/j.thromres.2020.08.024
  492. [Gratsianskaya S.Ye., Martynyuk T.V., Nakonechnikov S.N., Chazova I.Ye. Oral anticoagulants in patients with different forms of pulmonary arterial hypertension, aspects of the problem. Eurasian heart journal. 2017;(4):122-132. (in Russ.) https://doi.org/10.38109/2225-1685- 2017-4-122-132] [Chazova I.E., Martynyuk T.V., Filippov E.V., et al. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2). Terapevticheskii arkhiv 2016;88(10):63-73. (In Russ.) https://doi.org/10.17116/terarkh201688663-73] 2. Circulation. 2008; 117:3010–3019. https://doi.org/10.1161/ circulationaha.107.742510   combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011;51:1071–1078. https://doi. org/10.1177/0091270010379808 302. https://doi.org/10.1183/09031936.00087114
  493. [Martynyuk TV. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension 2019;16(2):12-27. (in Russ.) https://doi.org/10.26442/ 2075082X.2019.2.190352]
  494. [Rezukhina E.A., Rodnenkov O.V., Martynyuk T.V. Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation. Eurasian heart journal. 2023;(1):94-99. (In Russ.) https://doi. org/10.38109/2225-1685-2023-1-94-99]   0.2020.12.000840 [Shmalts AA, Gorbachevsky SV. Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia. Terapevticheskii arkhiv 2020;92(12):80-85. (in Russ.) https:// doi.org/10.26442/00403660.2020.12.000840] [Lyapina IN, Zvereva TN, Martynyuk TV. Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review. Consilium Medicum. 2022;24(10):688–695. (in Russ.) https:// doi.org/10.26442/20751753.2022.10.201875] 286. https://doi.org/10.1016/j.chest.2021.01.066 1124. https://doi.org/10.26442/00403660.2021.09.201014
  495. [Martynyuk TV, Shmalts AA, Gorbachevsky SV, Chazova IE. Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. Terapevticheskii arkhiv 2021;93(9):1117- 1124. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201014]
  496. [Martynyuk TV, Nakonechnikov SN, Chazova IY. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension. Terapevticheskii arkhiv 2018;90(4):72-80. (in Russ.) https://ter-arkhiv.ru/0040-3660/ article/view/32480]
  497. [Chazova IE, Martynyuk T.V. on behalf of the authors. Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension". Terapevticheskii arkhiv 2019;91(3):114-116. (in Russ.). https://doi.or g/10.26442/00403660.2019.03.000185]
  498. [Shmal’ts A.A., Nishonov N.A. Atrial septostomy for patients with pulmonary hypertension; Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2015;57(5):18-25. (in Russ.)] 3-58-64[Shmalts A.A., Gorbachevsky S.V., Martynyuk T.V., Nakonechnikov S.N. Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease. Eurasian heart journal. 2022;(3):58-64. (In Russ.) https://doi.org/10.38109/2225-1685-2022-3-58-64]
  499. [Gorbachevsky S.V., Shmalts A.A., Plotnikova L.R. Pulmonary hypertension in children with congenital heart defects. M.: Kedr LLC; 2018. (In Russ.). ISBN 978-5-91487-115-1] 66-6-23-32
  500. [Baryshnikova I.Yu., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(6):23-32. (In Russ.). https:// doi.org/10.21508/1027-4065-2021-66-6-23-32]
  501. [Sobolev A.V., Shmalts A.A. Endovascular diagnostics of pulmonary hypertension associated with congenital heart defects. Part 1. Cardiac catheterization and angiography. Russian journal of endovascular surgery. 2021;8(3):263-71. (In Russ.) https://doi.org/10.24183/2409- 4080-2021-8-3-263-271]
  502. [Gorbachevsky S.V., Shmalts A.A. Primary examination. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:20-34. (In Russ.) ISBN: 978-5-7982- 0450-2]
  503. [Baryshnikova I.Yu., Shmalts A.A. Echocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:35-52. (In Russ.) ISBN: 978-5-7982-0450-2]
  504. МЗ РФ; 2023:53-67. ISBN: 978-5-7982-0450-2
  505. [Yurpolskaya L.A., Shmalts A.A. X-ray computed tomography and magnetic resonance imaging. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:53-67. (In Russ.) ISBN: 978-5-7982-0450-2]
  506. «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:68-83. ISBN: 978-5- 7982-0450-2
  507. [Sobolev A.V., Shmalts A.A. Cardiac catheterization and angiocardiography. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:68-83. (In Russ.) ISBN: 978-5-7982-0450-2]  
  508. [Glushko L.A., Shmalts A.A. Assessment of the state of the cardiorespiratory system. In the book: Gorbachevsky S.V., Shmalts
  509. A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:109-124. (In Russ.) ISBN: 978-5-7982-0450-2]
  510. [Shmalts A.A., Gorbachevsky S.V. Vasoreactivity test. In the book: Gorbachevsky S.V., Shmalts A.A. (ed.) Diagnosis of pulmonary hypertension in congenital heart defects. M.: A.N. Bakulev National medical research center for cardiovascular surgery Ministry of Health of the Russian Federation; 2023:99-108. (In Russ.) ISBN: 978-5-7982- 0450-2]
  511. [Shmal’ts A.A., Belkina M.V., Gorbachevskiy S.V. Specific pulmonary vasodilators after Fontan operation. Detskie bolezni serdtsa i sosudov (Children's Heart and Vascular Diseases). 2017;14(1):16–24 (in Russ.) https://dx.doi.org/10.24022/1810-0686-2017-14-1-16-24]
  512. [Shmalts AA, Gorbachevsky SV. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii arkhiv 2021;93(9):1106-1116. (In Russ.) https://doi.org/10.26442/00 403660.2021.09.201022]
  513. [Guseva N.G., Guseva H.G. Systemic scleroderma is a multidisciplinary problem. Rheumatology Science and Practice. 2011;49(2):10-14. (In Russ.) https://doi.org/10.14412/1995-4484-2011-596] тельной ткани: данные ревматологического экспертного центра. Научно-практическая ревматология 2015;53(1):51-57. https://doi. org/10.14412/1995-4484-2015-51-57
  514. [Nikolaeva E.V., Korsakova Yu.O., Kurmukov I.A., et al. Possibilities for echocardiographic determination of pulmonary artery pressure in patients with systemic connective tissue diseases: data of a rheumatology expert center. Rheumatology Science and Practice. 2015;53(1):51-57. (In Russ.) https://doi.org/10.14412/1995-4484-2015-51-57]
  515. [Yudkina N.N., Nikolaeva E.V., Martynyuk T.V., Volkov A.V. The clinical subtype of systemic scleroderma associated with pulmonary arterial hypertension. Kardiologicheskiy vestnik (Cardiological Bulletin). 2017;4:66–75. (in Russ.)] 10.0. HIV Med. 2020;21:617–624. https://doi.org/10.1111/hiv.12878 6-708-714
  516. [Koneva O.A., Ovsyannikova O.B., Starovoytova M.N., et al. Isolated decrease of the lung diffusing capacity in patients with systemic sclerosis without pulmonary arterial hypertension: a long-term prospective study. Pulmonologiya. 2016;26(6):708-714. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-6-708-714] Merkulov E.V., Sapelnikov O.V., Vlasova E.E., et al. Complications of the Catheter Treatment of Atrial Fibrillation: Stenosis of All Pulmonary Veins after Radiofrequency Ablation. Kardiologiia. 2019;59(5):92-96. (In Russ.) https://doi.org/10.18087/cardio.2019.5.10260] 2022-11-4-118-129 [Lyapina I. N., Teplova Yu. E., Martynyuk T. V. Phenotype of patients with pulmonary hypertension due to left heart disease: features of pathophysiology and differential diagnosis. Complex Issues of Cardiovascular Diseases. 2022;11(4):118-129. (In Russ.) https://doi. org/10.17802/2306-1278-2022-11-4-118-129 1562. https://doi.org/10.1161/circulationaha.107.716373 2021 201305070-00003 [Sarybaev A.Sh., Sydykov A.S., Sartmyrzaeva M.A., et al. High altitude pulmonary hypertension («Mirrakhimov's disease»). Eurasian heart journal. 2016;(4):76-83. (In Russ.) https://doi.org/10.38109/2225- 1685-2016-4-76-83] [Chernyavsky A.M., Edemsky A.G., Novikova N.V., et al. Surgical treatment of chronic thromboembolic pulmonary hypertension./ National Medical Research Center named after E.N. Meshalkina; under the general editorship of A.M. Chernyavsky. — Novosibirsk: National Medical Research Center: Publishing House SB RAS, 2019.317 p. (In Russ.) ISBN: 978-5-7692-1665-7] [Akchurin R.S., Mershin K.V., Tabakyan E.A., et al. Surgical treatment of chronic thromboembolic pulmonary hypertension: modern trends and own experience. Eurasian heart journal. 2016;(2):40-47. (In Russ.) https://doi.org/10.38109/2225-1685-2016-2-40-47] [Cherniavskiĭ AM, Edemskiĭ AG, Cherniavskiĭ MA, et al. 5-year surgical results in patients with chronic postembolic pulmonary hypertension. Pirogov Russian Journal of Surgery = Khirurgiya. Zurnal im. N.I. Pirogova. 2017;(2):21-24. (In Russ.) https://doi.org/10.17116/ hirurgia2017221-24] [Valieva Z.S., Martynyuk T.V. Choice of specific and anticoagulant therapy in patients with newly diagnosed chronic thromboembolic pulmonary hypertension, depending on operability status. Russian Journal of Cardiology. 2023;28(3):5231. (In Russ.) https://doi. org/10.15829/1560-4071-2023-5231]
  517. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:1801913. https://doi. org/10.1183/13993003.01913-2018
  518. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022; 43(38):3618– 3731. http://dx.doi.org/10.1093/eurheartj/ehac237
  519. Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомен-
  520. Мартынюк Т.В. Лёгочная гипертензия: диагностика и лечение. Москва, 2018. Серия Библиотека ФГБУ «НМИЦ кардиологии»
  521. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015;46(4):903-975. http:// dx.doi.org/10.1183/13993003.01177-2015
  522. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., др. Клинические ре- комендации по диагностике и лечению хронической тромбоэмбо- лической лёгочной гипертензии. (I часть). Терапевтический архив 2016; 88(9):90-101. https://doi.org/10.17116/terarkh201688990-101 [Chazova I.E., Martynyuk T.V., Filippov E.V., et al. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. (Part I). Therapeutic Archive 2016;88(9):90-101 (in Russ.). https://doi.org/10.17116/terarkh201688990-101]
  523. Kim N.H., Delcroix M., Jais X. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53:1801915. https://doi. org/10.1183/13993003.01915-2018
  524. Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:69-78. https://doi.org/10.1016/j.ijcard.2018.08.079
  525. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские кли- нические рекомендации по диагностике и лечению лёгочной ги- пертензии (2019). Евразийский Кардиологический Журнал 2020;
  526. Чазова И.Е., Мартынюк Т.В. Лёгочная гипертензия. – Москва. Практика. 2015; 928с.
  527. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111. https://doi.org/10.1161/ circulationaha.104.488486
  528. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Лёгочная артериаль- ная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив 2019; 91(1):10–31. https://doi.org/10.26442/00403660.2019.01.000024
  529. Chazova IE, Martynyuk TV, Valieva ZS, et al. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. BioMed Research International. 2020:6836973. PMID: 32626754. https://doi.org/10.1155/2020/6836973
  530. Чазова И.Е., Горбачевский С.В., Мартынюк Т.В., др. Евразийские рекомендации по диагностике и лечению лёгочной гипертензии, ассоциированной с врождёнными пороками сердца у взрослых (2021). Евразийский кардиологический журнал. 2022;2:6-70. https://doi.org/10.38109/2225-1685-2022-2-6-7
  531. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV- related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113. https://
  532. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno- occlusive disease. Eur Respir J 2009;33:189–200. https://doi. org/10.1183/09031936.00090608
  533. Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-
  534. Мартынюк Т.В. «Лёгочная гипертензия вследствие патологии ле- вых отделов сердца». Глава в руководстве для врачей «Лёгочная гипертензия» под ред. Авдеева С.Н. (2 издание). ГЭОТАР-МЕДИА, Москва, 2019. С. 213-254.
  535. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194. https://doi.org/10.1164/rccm.200401-006oc
  536. Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol 2013; 168(3):e89–e90. https://doi.org/10.1016/j. ijcard.2013.07.129
  537. Leon-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6:147-157. https://doi.org/10.1089/ham.2005.6.147
  538. Авдеев С.Н., Барбараш О.Л., Баутин А.Е., др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипер- тензия. Клинические рекомендации 2020. Российский кардиоло- гический журнал. 2021;26(12):4683. https://doi.org/10.15829/1560- 4071-2021-4683
  539. Montani D, Girerd B, Jais X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2020; 58: 2004229. https://doi.org/10.1183/13993003.04229-2020
  540. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34(4):888–894. https://doi.org/10.1183/09031936.00145608
  541. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297–3317. https://doi.org/10.1093/eurheartj/ehz641
  542. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8:873–884. https://doi.org/10.1016/s2213-2600(20)30317-9
  543. Frost A, Badesch D, Simon JR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53:1801904. https://doi. org/10.1183/13993003.01904-2018
  544. Morrell N, Adnot S, Archer S, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S20-S31. https://doi.org/10.1016/j.jacc.2009.04.018
  545. Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:4–10. https://doi.org/10.1016/j.ijcard.2018.09.070
  546. Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:53–62. https://doi.org/10.1016/j.ijcard.2018.08.080
  547. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41:1292– 1301. https://doi.org/10.1183/09031936.00079512
  548. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:1801914. https://doi.org/10.1183/13993003.01914-2018
  549. Наконечников С.Н., Зыков К.А., Мартынюк Т.В., др. Профиль про- воспалительных маркеров у пациентов с различными формами лёгочной гипертензии. Системные гипертензии 2010; 3:61-67. https://doi.org/10.26442/SG28888
  550. Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26(143):160112. https://doi.org/10.1183/16000617.0112-2016
  551. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Лёгочная артери- альная гипертензия, ассоциированная с врождёнными пороками сердца у взрослых. Методическое пособие./ НЦССХ им. А. Н. Ба- кулева РАМН, 2016 г. ISBN: 978-5-7982-0368-0
  552. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306–322. https://doi. org/10.1016/s2213-2600(15)00543-3
  553. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ 2021; 11:2045894020977300. https://doi. org/10.1177/2045894020977300
  554. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107(2):216–223. https://doi.org/10.7326/0003-4819-107-2-216
  555. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (2):156–163. https://doi.org/10.1161/circulationaha.109.911818
  556. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137(2):376–387. https://doi.org/10.1378/chest.09-1140
  557. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168(2):871–880. https://doi. org/10.1016/j.ijcard.2012.10.026
  558. Чазова И.Е., Архипова О.А., Валиева З.С., др. Лёгочная гипертен- зия в России: первые результаты национального регистра. Тера- певтический архив 2014; 86(9):56-64.
  559. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019; 53(6):1900985. https://doi.org/10.1183/13993003.00985-2019
  560. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472. https:// doi.org/10.1056/nejmra010902
  561. Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57(6):2002828. https://doi.org/10.1183/13993003.02828-2020
  562. Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018 Jul;107(7):548-553. https://doi.org/10.1007/ s00392-018-1215-5
  563. Чазова И.Е., Валиева З.С., Наконечников С.Н. др. Особенности клинико-функционального и гемодинамического профиля, ле- карственной терапии и оценка прогноза у пациентов с неопера- бельной хронической тромбоэмболической и идиопатической лёгочной гипертензией по данным Российского регистра. Тера- певтический архив 2019; 91(9):77-87. https://doi.org/10.26442/004
  564. Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465. https://doi.org/10.1183/13993003.00465-
  565. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские рекомендации по диагностике и лечению хронической тром- боэмболической легочной гипертензии (2020). Евразий-
  566. Алокова Ф.Х., Блинова Е.В., Сахнова Т.А., др. Изменения электро- кардиограммы в 12 отведениях у больных с идиопатической ле- гочной гипертензией. Медицинский алфавит. 2018;4(36):29-35. [Alokova F.Kh., Blinova E.V., Sakhnova T.A., et al. Changes of the electrocardiogram in 12 leads in patients with idiopathic pulmonary hypertension. Medical alphabet. 2018;4(36):29-35. (In Russ.)]
  567. Klok FA, Surie S, Kempf T, et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011;128:21-26. https://doi.org/10.1016/j.thromres.2011.03.004
  568. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132. https://doi. org/10.1016/j.ahj.2006.09.008
  569. Kamphuis VP, Haeck ML, Wagner GS, et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol 2014; 47(2):175-
  570. Сахнова Т.А., Блинова Е.В., Белевская А.А., др. Сопоставление интегральных показателей векторкардиограммы с данными эхо- кардиографического исследования у больных идиопатической и хронической тромбоэмболической лёгочной гипертензией. Тера- певтический архив 2019;3:11-16. https://doi.org/10.26442/0040366 0.2019.03.000043
  571. Remy-Jardin M, Ryerson CJ, Schiebler ML, et al. Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. Eur Respir J 2021;57:2004455. https://doi.org/10.1183/13993003.04455- 2020
  572. Коробкова И.З., Лазуткина В.К., Низовцова Л.А., Ридэн Т.В. Мето- дические аспекты рентгенологической оценки лёгочной гипертен- зии. ВРР 2015;4:45-53. https://doi.org/10.20862/0042-4676-2015-0- 4-14-21
  573. Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonaryhypertension. Ann Thorac Med 2017;12:61-73. https:// doi.org/10.4103/1817-1737.203742
  574. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41:1028- 1035. https://doi.org/10.1016/s0735-1097(02)02964-9
  575. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults:a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685–713. https://doi.org/10.1016/j. echo.2010.05.010
  576. Белевская А.А., Дадачева З.Х., Саидова М.А., др. Возможности эхокардиографии в диагностике лёгочной гипертензии и оценке ремоделирования сердца. Лечебное дело 2015;1:111-121. [Belevskaya A.A., Dadacheva Z.Kh., Saidova M.A., et al. The Role of Echocardiography in Diagnosis of Pulmonary Hypertension and Assessment of Heart Remodeling. General Medicine 2015;1:111-121. (in Russ.)]
  577. Rich JD, Shah SJ, Swamy RS et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139(5):988-993. https://doi.org/10.1378/chest.10-1269
  578. Finkelhor RS, Lewis SA, Pillai D. Limitations and strengths of doppler/ echo pulmonary artery systolic pressure-right heart catheterization
  579. Magnino C, Omede P, Avenatti E, et al. Inaccuracy of right atrial pressure estimates through inferior vena cava indices. Am J Cardiol 2017; 120 (9):1667-1673. https://doi.org/10.1016/j.amjcard.2017.07.069
  580. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6 (2):359-65. https://doi.org/10.1016/s0735-1097(85)80172-8
  581. Greiner S, Jud A, Aurich M et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc. 2014; 3(4): e001103. https://doi. org/10.1161/jaha.114.001103
  582. Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open 2019; 22;9(12):e033084. https://doi. org/10.1136/bmjopen-2019-033084
  583. Amsallem M, Sternbach JM, Adigopula S, et al. Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography. J Am Soc Echocardiogr 2016; 29 (2):93-102 https://doi.org/10.1016/j.echo.2015.11.001
  584. Willis J, Henry F, Wild C, et al. Echocardiographic probability of pulmonary hypertension: a real world audit comparing 2015 and 2022 ESC guidelines. Abstract presented at ESC Congress 2023. Eur Heart J 2023; Vol. 44, Issue Supplement_October 2023; in press.
  585. D'Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013;168(4):4058-62. https:// doi.org/10.1016/j.ijcard.2013.07.005
  586. Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2018; 72(22):2778- 2788. https://doi.org/10.1016/j.jacc.2018.08.2201
  587. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30(6):1527-33. https://doi.org/10.1016/s0735-1097(97)00344-6
  588. Todaro MC, Carerj S, Zito C, et al. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. Am J Cardiovasc Dis. 2020;10(4):272-283. PMID: 33224574
  589. Vizza CD, Lang IM, Badagliacca R, et al. Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension? Am J Respir Crit Care Med 2022; 205(7):751-760. https://doi.org/10.1164/rccm.202109-2079pp
  590. Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging 2016; 9 (6):733-46. https://doi.org/10.1016/j.jcmg.2016.02.022
  591. Wright L, Dwyer N, Wahi S, Marwick TH. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2103-2111. https://doi.org/10.1016/j. jcmg.2018.08.017
  592. Farmakis IT, Demerouti E, Karyofyllis P, et al. Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility? J Clin Med. 2021;10(13):2826. https://doi. org/10.3390/jcm10132826
  593. Restrepo CS, Carswell AP. Aneurysms and pseudoaneurysms of the pulmonary vasculature. Semin Ultrasound CT MR. 2012;33(6):552-66. https://doi.org/10.1053/j.sult.2012.04.001
  594. Berger T, Siepe M, Simon B, et al. Pulmonary artery diameter: means and normal limits-assessment by computed tomography angiography. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):637-644. https:// doi.org/10.1093/icvts/ivab308
  595. Reisenauer JS, Said SM, Schaff HV, et al. Outcome of Surgical Repair of Pulmonary Artery Aneurysms: A Single-Center Experience With 38 Patients. Ann Thorac Surg. 2017;104(5):1605-1610. https://doi. org/10.1016/j.athoracsur.2017.03.077
  596. Duijnhouwer AL, Navarese EP, Van Dijk AP, et al. Aneurysm of the Pulmonary Artery, a Systematic Review and Critical Analysis of Current Literature. Congenit Heart Dis. 2016;11(2):102-109. https:// doi.org/10.1111/chd.12316
  597. Алеевская А.М., Выборов О.Н., Грамович В.В., Мартынюк Т.В. Особенности дифференциальной диагностики тромбоза лёгоч- ной артерии у пациентов с лёгочной гипертензией (клиническое
  598. Mesquita SM, Castro CR, Ikari NM et al. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med. 2004 Mar 15;116(6):369-
  599. Galiè N, Saia F, Palazzini M, et al. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. J Am Coll Cardiol 2017; 69(23):2808-2817. https://doi. org/10.1016/j.jacc.2017.03.597
  600. Kreibich M, Siepe M, Kroll J et al. Aneurysms of the pulmonary artery. Circulation 2015;131(3):310-316. https://doi.org/10.1161/ circulationaha.114.012907
  601. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680–684. https://doi.org/10.2967/ jnumed.106.039438
  602. Архипова О.А., Мартынюк Т.В., Самойленко Л.Е., др. Перфузи- онная сцинтиграфия лёгких у больных с лёгочной гипертензией различной этиологии. Евразийский Кардиологический Журнал. 2015;(4):20-25. https://doi.org/10.38109/2225-1685-2015-4-20-25
  603. Хроническая тромбоэмболическая лёгочная гипертензия: Руко- водство для врачей/ Под ред. Т.В. Мартынюк, акад. РАН И.Е. Чазо- вой. – Москва: ООО «Медицинское информационное агентство», 2023. 416 с. ISBN 978-5-907098-61-9
  604. Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/ perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019; 46:2429–2451. https://doi.org/10.1007/s00259-019-
  605. Masy M, Giordano J, Petyt G, et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018; 28:5100–5110. https://doi. org/10.1007/s00330-018-5467-2
  606. Dissaux, B, Le Floch PY, Robin P, et al. Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). Eur Radiol 2020;30:4857–4864. https://doi.org/10.1007/s00330-020-06836-3
  607. Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging 2017; 46: 1693–1697. https:// doi.org/10.1002/jmri.25714
  608. Swift AJ, Dwivedi K, Johns C, et al. Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;30:4918–4929. https://doi.org/10.1007/s00330-020-
  609. Dong C, Zhou M, Liu D, et al. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015;10:e0126985. https://doi.org/10.1371/journal.pone.0126985
  610. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung Transplant 2019;38:731–738. https://doi.org/10.1016/j. healun.2019.03.003
  611. Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014;112:598–605. https://doi.org/10.1160/th13-07-0538
  612. Tamura M, Yamada Y, Kawakami T, et al. Diagnostic accuracy of
  613. Веселова Т.Н., Демченкова А.Ю., Ен М.Ю., др. Оценка перфузии лёгких у больных хронической тромбоэмболической легочной гипертензией методами компьютерной томографии и сцинтигра- фии. REJR. 2022;12(2):94-103. https://doi.org/10.21569/2222-7415- 2022-12-2-94-103
  614. Meyer GMB, Spilimbergo FB, Altmayer S, et al. Correction to: Multiparametric magnetic resonance imaging in the assessment of pulmonary hypertension: initial experience of a one-stop study. Lung 2018;196:497. https://doi.org/10.1007/s00408-018-0130-x
  615. Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson 2012; 14:40–50. https://doi.org/10.1186/1532-429x-14-40
  616. Hatabu H, Ohno Y, Gefter WB, et al. Expanding applications of pulmonary MRI in the clinical evaluation of lung disorders: Fleischner society position paper. Radiology 2020; 297(2): 286-301. https://doi. org/10.1148/radiol.2020201138
  617. Kiely DG, Levin D, Hassoun P, et al. EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI).Pulm Circ. 2019; 9:2045894019841990. https://doi. org/10.1177/2045894019841990
  618. Van de Veerdonk MC, Marcus JT, Bogaard HJ, et al. State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series). Pulm Circ 2014;4(2):158–
  619. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011; 20(122):243-
  620. Swift AJ, Wild JM, Nagle SK, et al. Quantitative magnetic resonance imaging of pulmonary hypertension a practical approach to the current state of the art. J Thorac Imag 2014; 29(2):68-79. https://doi. org/10.1097/rti.0000000000000079
  621. Simpson CE, Damico RL, Kolb TM, Mathai SC, Khair RM, Sato T, Bourji K, Tedford RJ, Zimmerman SL, Hassoun PM. Ventricular mass as a prognostic imaging biomarker in incident pulmonary arterial hypertension. Eur Respir J. 2019 Apr 4;53(4):1802067. https://doi. org/10.1183/13993003.02067-2018
  622. Johns CS, Kiely DG, Rajaram S, et al. Diagnosis of pulmonary hypertension with cardiac MRI: derivation and validation of regression models. Radiology. 2019;290:61–68. https://doi.org/10.1148/ radiol.2018180603
  623. Johns CS, Swift AJ, Hughes PJC, Ohno Y, Schiebler M, Wild JM. Pulmonary MR angiography and perfusion imaging-A review of methods and applications. Eur J Radiol. 2017 Jan;86:361-370. https:// doi.org/10.1016/j.ejrad.2016.10.003
  624. Rajaram S, Swift AJ, Capener D, et al. Diagnostic accuracy of contrast- enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012; 22:310–317. https://doi. org/10.1007/s00330-011-2252-x
  625. Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2020;29:S1936-878X(20)30731–2.  https://doi.org/10.1016/j. jcmg.2020.08.013
  626. Saunders LC, Johns CS, Stewart NJ, et al. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018;20:78. https://doi.org/10.1186/s12968-018-0501-8
  627. Maschke SK, Schoenfeld CO, Kaireit TF, et al. MRI-derived regional biventricular function in patients with chronic thromboembolic pulmonary hypertension before and after pulmonary endarterectomy. Acad Radiol. 2018;25:1540–1547. https://doi.org/10.1016/j. acra.2018.04.002
  628. Sieren MM, Berlin C, Oechtering TH, et al. Comparison of 4D flow MRI to 2D flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. PLoS One 2019;
  629. Saunders LC, Johns CS, Stewart NJ, Oram CJE, Capener DA, Puntmann VO, Elliot CA, Condliffe RC, Kiely DG, Graves MJ, Wild JM, Swift AJ. Diagnostic and prognostic significance of cardiovascular magnetic resonance native myocardial T1 mapping in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2018 Dec 3;20(1):78. https:// doi.org/10.1186/s12968-018-0501-8
  630. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. SwissMed Wkly 2003; 133:163–169. https://doi. org/10.4414/smw.2003.10016
  631. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141:678–693. https://doi.org/10.1161/ circulationaha.116.022362
  632. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–818. https://doi.org/10.1056/NEJMoa1213917
  633. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122:1668-1673. https://doi.org/10.1378/chest.122.5.1668
  634. Шмальц А.А. Динамика дистанции шестиминутной ходьбы как показатель эффективности специфических лёгочных вазо- дилататоров. Рациональная Фармакотерапия в Кардиологии. 2022;18(3):342-349. https://doi.org/10.20996/1819-6446-2022-06-09
  635. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60(13): 1192–1201. https://doi.org/10.1016/j. jacc.2012.01.083
  636. Таран И.Н., Валиева З.С., Мартынюк Т.В., др. Вклад спировело- эргометрии в диагностический алгоритм обследования больных с лёгочной артериальной гипертензией. Медицинский алфавит. Больница (кардиология). 2016;3:19-23.
  637. Sherman AE, Saggar R. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin 2023;19(1):35-43. https://doi.org/10.1016/j.hfc.2022.08.015
  638. Dumitrescu D, Nagel C, Kovacs G, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017; 103:774–782. https://doi.org/10.1136/ heartjnl-2016-309981
  639. Torres-Castro R, Gimeno-Santos E, Vilaró J, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis.Eur Respir Review 2021; 30:200321. https://doi.org/10.1183/16000617.0321-2020
  640. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552. https:// doi.org/10.1016/j.jacc.2006.07.061
  641. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013;42:1586–1594. https://doi.org/10.1183/09031936.00050713
  642. Куропий Т.С., Данилов Н.М., Матчин Ю.Г. Сосудистые доступы к правым отделам сердца и легочным артериям: современное со- стояние вопроса. Кардиологический вестник 2022;17(3):23-28. https://doi.org/10.17116/Cardiobulletin20221703123
  643. Шмальц А.А., Мартынюк Т.В., Наконечников С.Н. Расчет гемодина- мики методом Фика при лёгочной гипертензии, ассоциированной с врождёнными пороками сердца. Евразийский кардиологиче- ский журнал 2022;(2):96-102. https://doi.org/10.38109/2225-1685- 2022-2-96-102
  644. Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: an analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol. 2017; 2:1090–1099. https://doi.org/10.1001/jamacardio.2017.2945
  645. Viray MC, Bonno EL, Gabrielle ND, et al. Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail. 2020;13:e007981. https://doi. org/10.1161/circheartfailure.120.007981
  646. Kubiak GM, Ciarka A, Biniecka M, et al. Right heart catheterization – background, physiological basics, and clinical implications. J Clin Med 2019;8:1331. https://doi.org/10.3390/ jcm8091331
  647. Kaemmerer H, Apitz C, Brockmeier K, et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-
  648. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698-e800. https://doi.org/10.1161/cir.0000000000000603
  649. Xu Q, Yang Y, Geng J, et al. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension. Chin Med J (Engl) 2017;130(4):382-391. https://doi. org/10.4103/0366-6999.199829
  650. Yang Y, Yu Y, Yuan P, et al. Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Eur Clin Respir J 2020; 14(7):611-621. https://doi.org/10.1111/crj.13173
  651. Юрпольская Л.А., Шмальц А.А. Рентгенография, рентгеновская компьютерная и магнитно-резонансная томография при лёгочной гипертензии, ассоциированной с врождёнными пороками серд- ца. Детские болезни сердца и сосудов 2021; 18(2):83-93. https:// dx.doi.org/10.24022/1810-0686-2021-18-2-83-93
  652. Shimokawahara H, Ogawa A, Mizoguchi H, et al. Vessel stretching is a cause of lumen enlargement immediately after balloon pulmonary angioplasty: intravascular ultrasound analysis in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018;11:e006010. https://doi.org/10.1161/ circinterventions.117.006010
  653. Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019;28:190023. https://doi.org/10.1183/16000617.0023-2019
  654. Morrisroe K, Huq M, Stevens W, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med. 2016;16:134. https://doi.org/10.1186/s12890-016-0296-z
  655. Волков А.В., Мартынюк Т.В. Лёгочная артериальная гипертензия при системных заболеваниях соединительной ткани: современ- ное состояние проблемы. Научно-практическая ревматология 2018;56(4):474−485. https://doi.org/10.14412/1995-4484-2018-474-485
  656. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–3800. https://doi.org/10.1002/art.21433
  657. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522–3530. https://doi.org/10.1002/art.30541
  658. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:the DETECT study. Ann Rheum Dis. 2014;73:1340–134. https://doi.org/10.1136/ annrheumdis-2013-203301
  659. Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:1801899. https://doi.org/10.1183/13993003.01899-2018
  660. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21:K9–K20. https://doi. org/10.1093/eurheartj/suz204
  661. Boon G, Ende-Verhaar YM, Bavalia R, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax 2021;76:1002– 1009. https://doi.org/10.1136/thoraxjnl-2020-216324
  662. Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39:4175–4181. https://doi. org/10.1093/eurheartj/ehx257
  663. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50:1700740. https://doi.org/10.1183/13993003.00740-2017
  664. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50:1700889. https://doi.org/10.1183/13993003.00889-
  665. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159: 337–346. https://doi.org/10.1016/j.chest.2020.08.2069
  666. Zelniker TA, Huscher D, Vonk-Noordegraaf A, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 2018;107(6):460-70. https://doi. org/10.1007/s00392-018-1207-5
  667. Provencher S, Chemla D, Herve P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir
  668. Khirfan G, Naal T, Abuhalimeh B, et al. Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One. 2018;13: e0191869. https://doi.org/10.1371/journal.pone.0191869
  669. Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transpl. 2020;39:300–309. https://doi.org/10.1016/j. healun.2019.12.013
  670. Nickel N, Golpon H, Greer M, et. al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 39:589–596. https://doi. org/10.1183/09031936.00092311
  671. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015; 34(3):362–368. https://doi. org/10.1016/j.healun.2014.08.020
  672. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013; 8(9):e72013. https://doi.org/10.1371/journal.pone.0072013
  673. Schiebler ML, Bhalla S, Runo J, et al. Magnetic resonance and computed tomography imaging of the structural and functional changes of pulmonary arterial hypertension. J Thorac Imaging. 2013; 28(3):178–193. https://doi.org/10.1097/rti.0b013e31828d5c48
  674. de Siqueira MEM, Pozo E, Fernandes VR, et al. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2016;18(1):39. https:// doi.org/10.1186/s12968-016-0258-x
  675. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131(2):402–409. https://doi. org/10.1378/chest.06-1758
  676. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482- 1489. https://doi.org/10.1161/circulationaha.106.618397
  677. Grunig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295. https://doi.org/10.1093/eurheartj/ehaa696
  678. Morris N.R., Kermeen F.D., Holland A.E. Exercise-based
  679. Chia KSW., Wong PKK., Faux SG. et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J 2017; 47(4):361–369. https://doi.org/10.1111/imj.13159
  680. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. https://doi. org/10.1093/eurheartj/ehac270
  681. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Россий- ский кардиологический журнал 2018, 3(155):91–134. https://doi. org/10.15829/1560-4071-2018-3-91-134
  682. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39: 3165–3241. https://doi.org/10.1093/ eurheartj/ehy340
  683. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015; 5:435-465. https://doi.org/10.1086/682230
  684. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013;143:1330–1336. https://doi.org/10.1378/ chest.12-0528
  685. Hill W., Holy R., Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ. 2018;10(4):2045894018785259. https://doi. org/10.1177/2045894018785259
  686. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013; 29:1–14. https://doi.org/10.3109/0951359
  687. Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41:1302–1307. https://doi. org/10.1183/09031936.00089212
  688. Thangamathesvaran L, Armenia SJ, Merchant AM. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. Updates Surg. 2018 Dec;70(4):521-528. https://doi. org/10.1007/s13304-018-0556-y
  689. Чазова И.Е, Мартынюк Т.В, Валиева З.С, др. Оценка бремени хро- нической тромбоэмболической лёгочной гипертензии в Россий- ской Федерации. Терапевтический архив. 2018; 9: 101-109. https:// doi.org/10.26442/terarkh2018909101-109
  690. Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res. 2020;196:251–
  691. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129:57–65. https://doi. org/10.1161/circulationaha.113.004526
  692. Грацианская С.Е., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Проблемные аспекты применения оральных антикоагулянтов у пациентов с легочной артериальной гипертензией различного ге- неза. Евразийский Кардиологический Журнал. 2017;(4):122-132. https://doi.org/10.38109/2225-1685-2017-4-122-132
  693. Чазова И.Е., Мартынюк Т.В., Филиппов Е.В., соавт. Клинические ре- комендации по диагностике и лечению хронической тромбоэмбо- лической лёгочной гипертензии. (2 ЧАСТЬ). Терапевтический архив 2016; 88(10):63-73. https://doi.org/10.17116/terarkh201688663-73
  694. Mancuso L, Scordato F, Pieri M, et al. Management of portopulmonary hypertension: new perspectives. World J Gastroenterol. 2013;19:8252– 8257. https://doi.org/10.3748/wjg.v19.i45.8252
  695. Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education 2017; 17(7):228–234. https://doi. org/10.1093/bjaed/mkw074
  696. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21:K46– K53. https://doi.org/10.1093/eurheartj/suz207
  697. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-792. https://doi.org/10.1378/ chest.114.3.787
  698. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132. https://doi. org/10.1016/j.ahj.2006.09.008
  699. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 2013; 167:2300–2305. https://doi.org/10.1016/j.ijcard.2012.06.024
  700. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53:1801906. https://doi. org/10.1183/13993003.01906-2018
  701. Jentzer JC, Mathier, MA. Pulmonary Hypertension in the Intensive Care Unit J Intensive Care Med 2016; 31(6):369–385. https://doi. org/10.1177/0885066615583652
  702. Sztrymf B, Souza R, Bertoletti I, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35:1286–1293. https://doi.org/10.1183/09031936.00070209
  703. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81. https://doi.org/10.1056/ nejm199207093270203
  704. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp Pharmacol. 2013;218:199–227. https://doi. org/10.1007/978-3-642-38664-0_9
  705. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and
  706. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903. https://doi. org/10.1056/nejmoa012212
  707. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–344. https://doi.org/10.1183/09031936.00138706
  708. Sitbon J, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2019; 7(7):594-604. https://doi.org/10.1016/s2213-2600(19)30091-8
  709. Galie N, Ghofrani HA, Torbicki A, et al, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148– 2157. https://doi.org/10.1056/nejmoa050010
  710. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069. https://doi.org/10.1161/01. cir.0000099502.17776.c2
  711. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–2903. https://doi.org/10.1161/circulationaha.108.839274
  712. Lichtblau, M., Harzheim, D., Ehlken, N., et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung 193; 1:105–112. https://doi.org/10.1007/s00408-014-9657-7
  713. Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir
  714. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011;20:567–576. https://doi.org/10.1517/13543784.2011.565048
  715. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013;369:330-40. https://doi.org/10.1056/nejmoa1209655
  716. Ghofrani HA, D’Armini AM, Grimminger F, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-329. https://doi. org/10.1056/nejmoa1209657
  717. Ghofrani H-A, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomized, long- term extension trial. Lancet Respir Med. 2016; 4:361–371. https://doi. org/10.1016/s2213-2600(16)30019-4
  718. Simonneau G, D’Armini AM, Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015;45(5):1293-
  719. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009; 18(111):29–34. https://doi. org/10.1183/09059180.00011111
  720. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263. https://doi.org/10.1164/rccm.200603-358oc
  721. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694. https://doi.org/10.1183/09031936.06. 00057906
  722. Мартынюк Т.В. Оценка приверженности пациентов с лёгочной гипертензией лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового неинтервенционного ис- следования IVENT. Системные гипертензии. 2019;16(2):12-27. https://doi.org/10.26442/2075082X.2019.2.190352
  723. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533. https://doi.org/10.1056/nejmoa1503184
  724. Резухина Е.А., Родненков О.В., Мартынюк Т.В. Портрет типичного пациента с лёгочной артериальной гипертензией для назначе- ния агониста простациклиновых рецепторов селексипага. Евра- зийский Кардиологический Журнал 2023;(1):94-99. https://doi. org/10.38109/2225-1685-2023-1-94-99
  725. Boucly A, Savale, L, Jaïs, X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J of Respir and Crit Care Med. 2021; 204(7):842–854. https://doi. org/10.1164/rccm.202009-3698oc
  726. Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S:37–45. https:// doi.org/10.1016/j.ijcard.2018.08.082
  727. Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomized, controlled AMBITION study. Lancet Respir Med 2016;4:894–901. https://doi.org/10.1016/S2213-2600(16)30307-1
  728. McLaughlin VV, Vachiery, JL, Oudiz, RJ, et al. (AMBITION Study Group). Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J of Heart and Lung transplantation: the official publication of the International Society for Heart Transplantation. 2019; 38(12):1286–1295. https:// doi.org/10.1016/j.healun.2019.09.010
  729. Lang I M, Palazzini, M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl. 2019; 21(Suppl K):K21–K28. https://doi.org/10.1093/eurheartj/suz205
  730. Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной комбинированной специфической терапии лёгочной артериальной гипертензии в Российской Федерации. Терапевти- ческий архив 2020; 92(12):80-85. https://doi.org/10.26442/0040366
  731. Ляпина И.Н., Зверева Т.Н., Мартынюк Т.В. Возможности комбини- рованной терапии в лечении пациентов с впервые установленным диагнозом лёгочной артериальной гипертензии промежуточного риска. Consilium Medicum 2022; 24(10):688-695. https://doi.org/10. 26442/20751753.2022.10.201875
  732. Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834–844. https://doi.org/10.1056/nejmoa1413687
  733. Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102– 1110. https://doi.org/10.1164/rccm.201507-1398oc
  734. Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J;56(3):2000673. https://doi.org/10.1183/13993003.00673-2020
  735. Macitentan/Tadalafil Fixed-Dose Combination in Pulmonary Arterial Hypertension - A DUE. Presented by Dr. Kelly Chin at the American College of Cardiology Annual Scientific Session (ACC.23/WCC), New Orleans, LA, March 6, 2023. https://www.acc.org/Latest-in-Cardiology/ Clinical-Trials/2023/03/01/23/47/a-due
  736. Chin KM, Sitbon O, Doelberg M, et al. Three versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 2021;78:1393–1403. https://doi.org/10.1016/j. jacc.2021.07.057
  737. Thakrar MV, Weatherald JC, Varughese RA, et al. Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study. J Heart Lung Transplant. 2018;37(4S):S53-S54. https://doi.org/10.1016/j.healun.2018.01.115
  738. Satoshi A, Yoshihiro D, Kaori I, et al. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) – Protocol of a Multicenter Randomized Control Trial. Circ Rep. 2021;3(2):105-109. https://doi.org/10.1253/ circrep.cr-20-0133
  739. Gaine S, Sitbon O, Channick RN, et al. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest 2021; 160(1):277–
  740. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46(2):405-413. https://doi. org/10.1183/13993003.02044-2014
  741. Galiè, N. Gaine S, Channick R, et al. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in therapy 2022; 39(1):796-810. https://doi.org/10.1007/ s12325-021-01898-1
  742. Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50(3):1602425. https://doi.org/10.1183/13993003.02425-2016
  743. Taran IN, Belevskaya AA, Saidova MA, et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung 2018; 196(6):745-753. https://doi.org/10.1007/s00408-018-0160-4
  744. Мартынюк Т.В., Шмальц А.А., Горбачевский С.В., Чазова И.Е. Оп- тимизация специфической терапии лёгочной гипертензии: воз- можности риоцигуата. Терапевтический архив 2021; 93(9):1117–
  745. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Новые горизонты применения антагониста рецепторов эндотелина второго поколе- ния мацитентана у пациентов с лёгочной гипертензией. Терапев- тический архив 2018; 2018:72-80. https://ter-arkhiv.ru/0040-3660/ article/view/32480
  746. Hoeper, MM, Al-Hiti, H, Benza, RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet Respir Med 2021; 9(6)573–584. https://doi.org/10.1016/s2213-2600(20)30532-4
  747. Чазова И.Е., Мартынюк Т.В. от имени авторов. Резолюция эксперт- ного совета по проблеме лёгочной артериальной гипертензии «Ме- няя парадигму лечения пациентов с ЛАГ». Терапевтический архив 2019;91(3):114-116. https://doi.org/10.26442/00403660.2019.03.000185
  748. Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. Front Cardiovasc Med 2022;9:977110. https://doi.org/10.3389/fcvm.2022.977110
  749. Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. J Cardiol. 2015; 66(4):304-314. https://doi.org/10.1016/j.jjcc.2015.02.001
  750. Gorbachevsky SV, Shmalts AA, Dadabaev GM, et al. Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics (Basel). 2020;10(9):725. https://doi.org/10.3390/ diagnostics10090725
  751. Горбачевский С.В., Пурсанов М.Г., Шмальц А.А., др. Результаты атриосептостомии со стентированием у больных с идиопатиче- ской и схожими формами лёгочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019; 61(2):100-113. https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113 [Gorbachevsky S.V., Pursanov M.G., Shmalts A.A., et al. Results of stent fenestration of the interatrial septum in patients with idiopathic and similar forms of pulmonary arterial hypertension. Russian Journal of Thoracic and Cardiovascular Surgery. 2019;61(2):100–13 (in Russ.). https://dx.doi.org/10.24022/0236-2791-2019-61-2-100-113]
  752. Шмальц А.А., Нишонов Н.А. Атриосептостомия у больных с лё- гочной гипертензией. Грудная и сердечно-сосудистая хирургия. 2015;57(5):18-25.
  753. Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2019; 156:53–63. https:// doi.org/10.1016/j.chest.2019.03.003
  754. Bartolome SD., Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016; 21(3):347–356. https://doi. org/10.1007/s10741-016-9562-7
  755. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019; 53:1801906. https://doi. org/10.1183/13993003.01906-2018
  756. Шмальц А.А., Горбачевский С.В., Мартынюк Т.В., Наконечников С.Н. Тест на вазореактивность при лёгочной гипертензии, ассоциирован- ной с врождёнными пороками сердца. Евразийский кардиологиче- ский журнал 2022; 3:58-64. https://doi.org/10.38109/2225-1685-2022-
  757. Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Лёгочная гипер- тензия у детей с врождёнными пороками сердца. М.: ООО «Кедр»; 2018. ISBN 978-5-91487-115-1
  758. Барышникова И.Ю., Шмальц А.А. Диагностика лёгочной гипертен- зии, ассоциированной с врождёнными пороками сердца. Часть 2. Эхокардиография. Российский вестник перинатологии и педиа- трии 2021;66:(6):23–32. https://doi.org/10.21508/1027-4065-2021-
  759. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42(6):563-645. https://doi.org/10.1093/eurheartj/ ehaa554
  760. Соболев А.В., Шмальц А.А. Эндоваскулярная диагностика лёгоч- ной гипертензии, ассоциированной с врождёнными пороками сердца. Часть 1. Катетеризация сердца и ангиокардиография. Эн- доваскулярная хирургия 2021; 8(3):263–71. https://doi.org/https:// doi.org/10.24183/2409-4080-2021-8-3-263-271
  761. Горбачевский С.В., Шмальц А.А. Первичное обследование. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной ги- пертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:20-34. ISBN: 978-5-7982-0450-2
  762. Барышникова И.Ю., Шмальц А.А. Эхокардиография. В кн.: Горба- чевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертен- зии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:35-52. ISBN: 978-5-7982-0450-2
  763. Юрпольская Л.А., Шмальц А.А. Рентгеновская компьютерная и магнитно-резонансная томография. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врож- дённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева»
  764. Соболев А.В., Шмальц А.А. Катетeризация сердца и ангиокардио- графия. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ
  765. Глушко Л.А., Шмальц А.А. Оценка состояния кардиреспираторной системы. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагности- ка лёгочной гипертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:109-124. ISBN: 978-5-7982-0450-2
  766. Шмальц А.А., Горбачевский С.В. Тест на вазореактивность. В кн.: Горбачевский С.В., Шмальц А.А. (ред.) Диагностика лёгочной ги- пертензии при врождённых пороках сердца. М.: ФГБУ «НМИЦ ССХ им. А.Н.Бакулева» МЗ РФ; 2023:99-108. ISBN: 978-5-7982-0450-2
  767. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ 2020;10:2045894020917885. https://doi.org/10.1177/2045894020917885
  768. Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфиче- ские легочные вазодилататоры после операции Фонтена. Дет- ские болезни сердца и сосудов 2017;14(1):16-24. https://dx.doi. org/10.24022/1810-0686-2017-14-1-16-24
  769. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48–54. https://doi. org/10.1161/circulationaha.106.630715
  770. Шмальц А.А., Горбачевский С.В. Доказательная база специфи- ческих лёгочных вазодилататоров у взрослых с врождёнными пороками сердца. Терапевтический архив. 2021;93(9):1106-1116. https://doi.org/10.26442/00403660.2021.09.201022
  771. Rubio-Rivas M, Royo C, Simeón CP, et al.. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-19. https://doi.org/10.1016/j. semarthrit.2014.05.010
  772. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8-18. https://doi.org/10.1183/09059180.00008211
  773. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. https://doi.org/10.1164/rccm.200510-1668oc
  774. Гусева, Н.Г. Системная склеродермия – мультидисциплинарная проблема. Научно-практическая ревматология 2011;49(2):10-14. https://doi.org/10.14412/1995-4484-2011-596
  775. Волков А.В., Мартынюк Т.В., Юдкина Н.Н. и др. Выживаемость пациентов с лёгочной артериальной гипертонией, ассоцииро- ванной с системной склеродермией. Терапевтический архив 2012;84(5):24-28. https://ter-arkhiv.ru/0040-3660/article/view/31020 [Volkov AV, Martynyuk TV, Yudkina NN, et al. Survival of patients with pulmonary arterial hypertension, associated with systemic sclerosis. Terapevticheskii arkhiv 2012;84(5):24-28. (In Russ.) https://ter-arkhiv. ru/0040-3660/article/view/31020]
  776. Attanasio U, Cuomo A, Pirozzi F, et al. Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. Int J Mol Sci. 2020;21(12):4430. https://doi.org/10.3390/ ijms21124430
  777. Николаева Е.В., Корсакова Ю.О., Курмуков И.А. и др. Возможно- сти эхокардиографического определения давления в лёгочной артерии у пациентов с системными заболеваниями соедини-
  778. Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В., Волков А.В. Клини- ческий субтип системной склеродермии, ассоциированный с лё- гочной артериальной гипертензией. Кардиологический вестник. 2017;12(4):66-75.
  779. Simpson CE, Damico RL, Hummers L, et al. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis- related pulmonary arterial hypertension. Pulm Circ. 2019;9(3): 2045894019859477. https://doi.org/10.1177/2045894019859477
  780. Santos-Gomes J, Gandra I, Adão R, et al. An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Front Cardiovasc Med 2022;9:924873. https://doi.org/10.3389/fcvm.2022.924873
  781. Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2015;17(1):7. https://doi. org/10.1186/s13075-015-0517-5
  782. Savale L, Guimas M, Ebstein N, Fertin M, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139. https://doi.org/10.1016/j. jhep.2020.02.021
  783. Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version
  784. Garry JD, Kolaitis NA, Kronmal R, et al. Pulmonary Hypertension Association Registry Investigators. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). J Heart Lung Transplant. 2022;41(12):1808-1818. https://doi. org/10.1016/j.healun.2022.08.019
  785. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40. https://doi.org/10.1097/01.aids.0000327514.60879.47
  786. Mularek-Kubzdela T, Ciurzyński M, Kowal Bielecka O, et al. An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease. Kardiol Pol. 2021;79(7-8):917-929. https://doi. org/10.33963/kp.a2021.0055
  787. Конева О.А., Овсянникова О.Б., Старовойтова М.Н., и др. Изо- лированное снижение диффузионной способности лёгких при системной склеродермии без лёгочной артериальной гипертен- зии: длительное проспективное наблюдение. Пульмонология. 2016;26(6):708-714. https://doi.org/10.18093/0869-0189-2016-26-
  788. Xanthouli P. Improved Survival for Patients with Systemic Sclerosis- associated Pulmonary Arterial Hypertension: For Real? Am J Respir Crit Care Med. 2023;207(3):238-240. https://doi.org/10.1164/ rccm.202210-2006ed
  789. Lazaro SM, Quezada Loaiza CA, Rodriguez Padial, et al. Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. Intern Med. 2021;51:355–365. https://doi.org/10.1111/imj.14751
  790. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012;141:906–915. https://doi.org/10.1378/chest.11-0160
  791. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212–1217. https://doi.org/10.1164/rccm.200404-445oc
  792. Certain MC, Chaumais MC, Jais X, et al. Characteristics and long- term outcomes of pulmonary venoocclusive disease induced by mitomycin C. Ches. 2021;159:1197–1207. https://doi.org/10.1016/j. chest.2020.09.238
  793. Montani D, Girerd B, Jais X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017;5:125–134. https:// doi.org/10.1016/s2213-2600(16)30438-6
  794. Меркулов Е.В., Сапельников О.В., Власова Э.Е., др. Осложнения катетерной абляции у пациента с фибрилляцией предсердий: стеноз всех лёгочных вен. Особенности эндоваскулярного ле- чения. Кардиология 2019;59(5):92-96. https://doi.org/10.18087/ cardio.2019.5.10260
  795. Assad TR, Hemnes AR, Larkin EK et al. Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. J Am Coll Cardiol 2016; 68(23):2525-2536. https://doi.org/10.1016/j. jacc.2016.09.942
  796. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009;136(1):37-43. https:// doi.org/10.1378/chest.08-2784
  797. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599–3726. https://doi.org/10.1093/eurheartj/ ehab368
  798. Bermejo J, Gonzalez-Mansilla A, Mombiela T, et al. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J Am Heart Assoc. 2021;10: e019949. https://doi.org/10.1161/jaha.120.019949
  799. Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50:1700578. https://doi.org/10.1183/13993003.00578- 2017
  800. D’Alto M, Romeo E, Argiento P, et al. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest. 2017;151:119–126. https://doi.org/10.1016/j.chest.2016.08.1439
  801. Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 2017;26:433–441. https://doi.org/10.1016/j.hlc.2016.09.004
  802. Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51:1701886. https://doi.org/10.1183/13993003.01886-2017
  803. Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018; 39:1255–1264. https://doi. org/10.1093/eurheartj/ehx700
  804. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonaryhypertension–a multi-center randomized study. Cardiology. 2008;109:273–280. https://doi.org/10.1159/000107791
  805. Cao JY, Wales KM, Cordina R, Lau EMT, Celermajer DS. Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. Int J Cardiol 2018;273:213–220. https://doi.org/10.1016/j.ijcard.2018.09.043
  806. Lilly LS. Pathophysiology of Heart Disease: An Introduction to Cardiovascular Medicine (p. 249). Wolters Kluwer Health, 7 th. ed., 2021; Kindle Edition. ISBN-13: 978-1975120597
  807. Ляпина И.Н., Теплова Ю.Е., Мартынюк Т.В. Фенотип пациентов с лёгочной гипертензией вследствие патологии левых отделов сердца: особенности патофизиологии и дифференциальной диа- гностики. Комплексные проблемы сердечно-сосудистых забо- леваний 2022;11(4):118-129. https://doi.org/10.17802/2306-1278-
  808. Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689–697. https://doi.org/10.1093/eurheartj/ehy809
  809. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555–
  810. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2014; 16:444–453. https://doi.org/10.1002/ejhf.47
  811. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. https://doi.org/10.1016/j.jacc.2007.07.078
  812. Obokata M, Reddy YNV, Shah SJ, et al. Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction. J Am Coll Cardiol 2019;74:2539–2550. https://doi. org/10.1016/j.jacc.2019.08.1062
  813. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011 Jul 12;124(2):164-174. https://doi.org/10.1161/ circulationaha.110.983866
  814. Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016; 68:368–378. https://doi. org/10.1016/j.jacc.2016.05.047
  815. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565–2573. https:// doi.org/10.1093/eurheartj/ehv336
  816. Dachs TM, Duca F, Rettl R, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 2022; 43(36):3402-3413. https://doi.org/10.1093/ eurheartj/ehac389
  817. Selim AM, Wadhwani L, Burdorf A, et al. Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019; 28(6):946-952. https://doi.org/10.1016/j.hlc.2018.04.299
  818. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose- ranging hemodynamic study. Circulation 2013; 128(5):502-11. https:// doi.org/10.1161/circulationaha.113.001458
  819. O’Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheteraortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 2015;8:e002358. https://doi.org/10.1161/ circinterventions.114.002358
  820. Tigges E, Blankenberg S, von Bardeleben RS, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018; 20:585–594. https://doi. org/10.1002/ejhf.864
  821. Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid- term outcomes. Heart 2012; 98:126–132. https://doi.org/10.1136/ heartjnl-2011-300705
  822. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561– 632. https://doi.org/10.1093/eurheartj/ehab395
  823. Schneider SR, Mayer LC, Lichtblau M, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomized crossover trial. ERJ Open Res 2021;7:00314-02021. https://doi.org/10.1183/23120541.00314-2021
  824. Groth A, Saxer S, Bader PR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018; 270:262–267. https://doi.org/10.1016/j.ijcard.2018.05.127
  825. Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100944. https://doi.org/10.1183/13993003.00944-2021
  826. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393- 2399. https://doi.org/10.1378/chest.128.4.2393
  827. Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58: 2101483. https://doi.org/10.1183/13993003.01483-
  828. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189–194. https://doi.org/10.1164/rccm.200401-006oc
  829. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752. https://doi.org/10.1378/ chest.129.3.746
  830. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531–1536. https://doi.org/10.1378/ chest.127.5.1531
  831. Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. Respirology. 2023; 28:262-72. https://doi.org/10.1111/resp.14378
  832. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158: 641–649. https://doi.org/10.7326/0003-4819-158-9-
  833. Gou Q, Shi R, Zhang X, Meng Q, Li X, Rong X, Gawa Z, Zhuoma N, Chen X. The Prevalence and Risk Factors of High-Altitude Pulmonary Hypertension Among Native Tibetans in Sichuan Province, China. High Alt Med Biol. 2020;21(4):327-335. https://doi.org/10.1089/ ham.2020.0022
  834. Сарыбаев А.Ш., Сыдыков А.С., Сартмырзаева М.А., др. Высоко- горная лёгочная гипертония («болезнь Миррахимова»). Евра- зийский кардиологический журнал 2016;(4):76-83. https://doi. org/10.38109/2225-1685-2016-4-76-83
  835. Sime F, Penaloza D, Ruiz L. Bradycardia, increased cardiac output, and reversal of pulmonary hypertension in altitude natives living at sea level. Br Heart J. 1971;33:647-657. https://doi.org/10.1136/ hrt.33.5.647
  836. Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005;60:683- 687. https://doi.org/10.1136/thx.2005.041954
  837. Antezana AM, Antezana G, Aparicio O, et al. Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. Eur Respir J 1998;12:1181-1185. https://doi.org/10.1183/09031936.98.12051181
  838. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).Eur Heart J 2020;41:543–603. https://doi.org/10.1093/ eurheartj/ehz405
  839. Swietlik EM, Ruggiero A, Fletcher AJ, et al. Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 2019;53:1801787. https://doi. org/10.1183/13993003.01787-2018
  840. Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol 2013 Aug 20;167(4):1193–1198. https://doi.org/10.1016/j.ijcard.2012.03.135
  841. Badagliacca R, Rischard F, Giudice FL, et al. Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart Lung Transplant 2022;41:780–790. https://doi.org/10.1016/j.healun.2022.02.021
  842. Jenkins DP, Biederman A, D"Armini AM, et al. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016;152(3):669–674. https://doi.org/10.1016/j.jtcvs.2016.02.062
  843. Чернявский А.М., Едемский А.Г., Новикова Н.В., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипертен- зии./ Национальный медицинский исследовательский центр име- ни Е.Н. Мешалкина; под общей редакцией А.М. Чернявского. — Новосибирск: НМИЦ: Издательство СО РАН, 2019.317 с. ISBN: 978-5-7692-1665-7
  844. Araszkiewicz A, Darocha S, Pietrasik A, et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol. 2019;278: 232–237. https://doi.org/10.1016/j.ijcard.2018.10.066
  845. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103. https://doi.org/10.1016/j. athoracsur.2012.04.004
  846. Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2018;37:250–258. https://doi.org/10.1016/j.healun. 2017.06.011
  847. Акчурин Р.С., Мершин К.В., Табакьян Е.А., др. Хирургическое лечение хронической тромбоэмболической лёгочной гипер- тензии: современные тенденции и собственный опыт. Евра- зийский Кардиологический Журнал. 2016; 2:40-47. https://doi. org/10.38109/2225-1685-2016-2-40-47
  848. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014;148:1005– 1011. https://doi.org/10.1016/j.jtcvs.2014.06.052
  849. Newnham M, Bunclark K, Abraham N, et al. CAMPHOR score: patient- reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2020;56:1902096. https://doi.org/10.1183/13993003.02096-2019
  850. Чернявский А.М., Едемский А.Г., Чернявский М.А., др. Пятилет- ние результаты хирургического лечения пациентов с хрониче- ской постэмболической лёгочной гипертензией Хирургия. Жур- нал им. Н.И. Пирогова. 2017;2:21-24. https://doi.org/10.17116/ hirurgia2017221-24
  851. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014;44:1635–1645. https://doi. org/10.1183/09031936.00050114
  852. Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018;52:1800589. https://doi.org/10.1183/13993003.00589- 2018
  853. Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med. 2022;10(10):961-971. https://doi.org/10.1016/s2213- 2600(22)00214-4
  854. Delcroix M, Staehler G, Gall H, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2018;52:1800248. https://doi.org/10.1183/13993003.00248- 2018
  855. Benza RL, Farber HW, Frost A, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018;37:836–843. https://doi.org/10.1016/j. healun.2018.02.015
  856. Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802004. https://doi. org/10.1183/13993003.02004-2018
  857. Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020;18:114–122. https://doi. org/10.1111/jth.14649
  858. Humbert MS, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2022;41:716–721. https://doi.org/10.1016/j. healun.2022.02.002
  859. Валиева З.С., Мартынюк Т.В. Выбор специфической и антикоагу- лянтной терапии у пациентов с впервые выявленной хронической тромбоэмболической легочной гипертензией в зависимости от статуса операбельности. Российский кардиологический журнал. 2023;28(3):5231. https://doi.org/10.15829/1560-4071-2023-5231
  860. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:685–694. https://doi. org/10.7326/m19-0291
  861. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high- risk patients with antiphospholipid syndrome. Blood 2018;132:1365– 1371. https://doi.org/10.1182/blood-2018-04-848333
  862. Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–794. https://doi.org/10.1016/s2213- 2600(17)30305-3
  863. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2010;139:85–91
  864. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hyper- tension. Eur Respir J. 2007;30:922–927. https://doi. org/10.1183/09031936.00039007
  865. Данилов Н.М., Матчин Ю.Г., Чазова И.Е., и др. Баллонная анги- опластика лёгочных артерий при неоперабельной хронической тромбоэмболической лёгочной гипертензии. Сonsilium Medicum 2016;5:59-61. https://consilium.orscience.ru/2075-1753/article/ view/94466[Danilov NM, Matchin YG, Chazova IE., et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Consilium Medicum 2016;18(5):59-61. (In Russ.) https://consilium.orscience.ru/2075-1753/article/view/94466]
  866. Mahmud E, Behnamfar O, Ang L,et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin 2018;7:103–117. https://doi.org/10.1016/j.iccl.2017.09.003
  867. Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1222-1230. https://doi.org/10.1253/circj.cj-18-0258
  868. Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes. 2017;10:e004029. https://doi.org/10.1161/circoutcomes.117.004029
  869. Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ 2018; 8:2045894018783996. https://doi. org/10.1177/2045894018783996
  870. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014;43:1394–1402. https://doi.org/10.1183/09031936.00012914
  871. Fukuda K, Hiroshi Date H, Doi S, et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019;83(4):842-945. https://doi.org/10.1253/circj.cj-66-0158
  872. Яровой С.Ю., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Структурные изменения легочных артерий после транслюминальной баллон- ной ангиопластики у пациентов с хронической тромбоэмболи- ческой легочной гипертензией. Евразийский Кардиологический Журнал. 2020;(4):12-20. https://doi.org/10.38109/2225-1685-2020-4-12-20[Yarovoy S.Y., Danilov N.M., Matchin Yu.G., Chazova I.E. Structural changes of the pulmonary arteries after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Eurasian heart journal. 2020;(4):12-20. (In Russ.) https://doi. org/10.38109/2225-1685-2020-4-12-20
  873. Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 2013;99:1415–1420. https://doi. org/10.1136/heartjnl-2012-303549
  874. Kurzyna M, Darocha S, Pietura R, et al. Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. Kardiol Pol 2017;75:645–654. https://doi.org/10.5603/kp.a2017.0091
  875. Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017;49:1602409. https://doi.org/10.1183/13993003.02409-2016
  876. Godinas L, Bonne L, Budts W, et al. Balloon pulmonary angioplasty for the treatment of nonoperable chronic thromboembolic pulmonary hypertension: single-center experience with low initial complication rate. J Vasc Interv Radiol 2019;30:1265-1272. https://doi. org/10.1016/j.jvir.2019.03.023
  877. Lang IM, Andreassen AK, Andersen A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function. Eur Heart J 2023;44(29):2659-2671. https://doi.org/10.1093/eurheartj/ehad413
  878. Shinkura Y, Nakayama K, Yanaka K, et al. Extensive revascularisation by balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension beyond haemodynamic normalisation. EuroIntervention 2018;13:2060-2068. https://doi.org/10.4244/eij-d-17-00157
  879. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-833. https://doi.org/10.1056/nejmoa1501035
  880. Danilov NM, Matchin YuG, Sagaydak OV, et al. Antecubital vein access for balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: safe new approach. Russian Open Medical Journal 2019;8:e0107. https://doi.org/10.15275/ rusomj.2019.0107
  881. Данилов Н.М., Яровой С.Ю., Елфимова Е.М., др. Клинические и рентгенологические аспекты реперфузионного отёка лёгких по- сле транслюминальной баллонной ангиопластики лёгочных ар- терий у пациентов с хронической тромбоэмболической лёгочной гипертензией. Системные гипертензии. 2022;19(3):23-30. https:// doi.org/10.38109/2075-082X-2022-3-23-30[Danilov N.M., Yarovoy S.Yu., Elfimova E.M., Chazova IE., et al. Clinical and radiological aspects of reperfusion pulmonary edema after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2022;19(3):23-30. (In Russ.) https://doi.org/10.38109/2075-082X-2022-3-23-30]
  882. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009;120(13):1248-. https://doi.org/10.1161/circulationaha.109.865881
  883. Валиева З.С., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Характеристика пациентов с хронической тромбоэмболической лёгочной гипертензией по данным российского национального регистра. Терапевтический архив. 2021;93(9):1058-1065. https:// doi.org/10.26442/00403660.2021.09.201037[Valieva ZS, Martynyuk TV, Nakonechnikov SN, Chazova IE. Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii arkhiv. 2021;93(9):1058-1065. (in Russ.) https://doi. org/10.26442/00403660.2021.09.201037]
  884. Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open. 2019; 9(12):e033084. https://doi. org/10.1136/bmjopen-2019-033084
  885. Gall H, Yogeswaran A, Fuge J, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine. 2021;34:100822. https:// doi.org/10.1016/j.eclinm.2021.100822
  886. D'Alto M., Di Maio M., Romeo E, et al. Echocardiographic probability of pulmonary hypertension: a validation study. Eur Respir J 2022;60:2102548. https://doi.org/10.1183/13993003.02548-2021
  887. Sydykov A, Mamazhakypov A, Maripov A, et al. Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. Int J Environ Res Public Health. 2021;18(4):1692. https:// doi.org/10.3390/ijerph1804192
  888. Soria R, Egger M, Scherrer U, et al. Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta-analysis. J Appl Physiol 2016;121(5):1151- 1159. https://doi.org/10.1152/japplphysiol.00394.2016
  889. Maripov A, Mamazhakypov A, Karagulova G, et al. High altitude pulmonary hypertension with severe right ventricular dysfunction. Int J Cardiol. 2013;168(3):e89-e90. https://doi.org/10.1016/j. ijcard.2013.07.129
  890. Grover RF, Vogel JH, Voigt GC, et al. Reversal of high altitude pulmonary hypertension. Am J Cardiol 1966;18:928-932. https://doi. org/10.1016/0002-9149(66)90443-7
  891. Maripov A, Muratali Uulu K, Satybaldyev S, Kushubakova N, Sarybaev A. Reversal of pulmonary hypertension in a patient with chronic mountain sickness after relocation to low altitude. J Clin Diagn Res. 2021 y;15(5):OD09-OD10. http://dx.doi.org/10.7860/ JCDR/2021/48309.14886
  892. Singh I, Khanna PK, Lal M, et al. High-altitude pulmonary hypertension. Lancet.  1965;2(7404):146-50.  https://doi.org/10.1016/s0140-6736(65)90229-1
  893. Richalet JP, Rivera-Ch M, Maignan M, et al. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med. 2008;177(12):1370-6. https://doi.org/10.1164/ rccm.200802-196oc
  894. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho- kinase inhibitor in patients with pulmonary arterial hypertension. Circ.J. Off. J. Jpn. Circ. Soc. 2006;70:174-178. https://doi.org/10.1253/ circj.70.174
  895. Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, et al. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur RespirJ. 2012;39:496-498. https://doi.org/10.1183/09031936.00095211
  896. Sommer N, Ghofrani H-A, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178:6-30. https://doi.org/10.1111/bph.15016
  897. Grimminger F, Schermuly RT, Ghofrani H-A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9:956-970. https://doi.org/10.1038/nrd3297

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

СПИСОК ЛИТЕРАТУРЫ
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*